PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9427327-2 1997 8-OH-DPAT increased the hybridization signal of the 5-HT1A receptor by 105% in the dorsal raphe nucleus (B7) 30 min after the injection. 8-Hydroxy-2-(di-n-propylamino)tetralin 0-9 5-hydroxytryptamine receptor 1A Homo sapiens 52-67 9427327-5 1997 At 8 h following 8-OH-DPAT injection, the effect had shifted to an increase in 5-HT1A receptor labeling by 68% in the B8 area. 8-Hydroxy-2-(di-n-propylamino)tetralin 17-26 5-hydroxytryptamine receptor 1A Homo sapiens 79-94 9369342-8 1997 Bromerguride decreased neither forskolin-stimulated cAMP accumulation nor extracellular 5-HT; instead, it antagonized the decrease of cAMP accumulation produced by 5-HT and the decrease of extracellular 5-HT produced by the 5-HT1A agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 239-283 5-hydroxytryptamine receptor 1A Homo sapiens 224-230 9347319-2 1997 The binding characteristics of tritium labeled 8-hydroxy-dipropyl-aminotetralin, or [3H]8-OH-DPAT, to the serotonin1A (5-HT1A) receptor in the stably transfected HeLa cell clone HA6 and in human cortical tissue were examined and compared. 8-Hydroxy-2-(di-n-propylamino)tetralin 88-97 5-hydroxytryptamine receptor 1A Homo sapiens 106-135 9369342-8 1997 Bromerguride decreased neither forskolin-stimulated cAMP accumulation nor extracellular 5-HT; instead, it antagonized the decrease of cAMP accumulation produced by 5-HT and the decrease of extracellular 5-HT produced by the 5-HT1A agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 285-294 5-hydroxytryptamine receptor 1A Homo sapiens 224-230 9316875-3 1997 Paroxetine reduced the oxytocin, adrenal corticotropic hormone and corticosterone responses to a challenge with the 5-HT1A agonist 8-hydroxy-2-(dipropylamino)tetralin. 8-Hydroxy-2-(di-n-propylamino)tetralin 131-166 5-hydroxytryptamine receptor 1A Homo sapiens 116-122 9314029-1 1997 Using in vivo extracellular recordings, we have examined the effect of the application of the prototypical 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), on the firing rate of locus coeruleus neurons. 8-Hydroxy-2-(di-n-propylamino)tetralin 131-170 5-hydroxytryptamine receptor 1A Homo sapiens 107-122 9314029-1 1997 Using in vivo extracellular recordings, we have examined the effect of the application of the prototypical 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), on the firing rate of locus coeruleus neurons. 8-Hydroxy-2-(di-n-propylamino)tetralin 172-181 5-hydroxytryptamine receptor 1A Homo sapiens 107-122 9313892-7 1997 Administration of the selective 5-HT1A antagonist, 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl] ethyl]-N-2-pyridinyl-benzamide hydrochloride (p-MPPI) (1.5 and 3.0 nmol), blocked the suppressive effects of 8-OHDPAT upon hissing. 8-Hydroxy-2-(di-n-propylamino)tetralin 206-214 5-hydroxytryptamine receptor 1A Homo sapiens 32-38 9218690-1 1997 The present study was undertaken to compare the properties of the [3H]8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) binding site in the dorsal raphe nucleus with the hippocampal 5-HT1A receptor. 8-Hydroxy-2-(di-n-propylamino)tetralin 66-79 5-hydroxytryptamine receptor 1A Homo sapiens 183-198 9272757-0 1997 On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635. 8-Hydroxy-2-(di-n-propylamino)tetralin 79-88 5-hydroxytryptamine receptor 1A Homo sapiens 61-68 9272757-0 1997 On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635. 8-Hydroxy-2-(di-n-propylamino)tetralin 79-88 5-hydroxytryptamine receptor 1A Homo sapiens 189-195 9272757-9 1997 These data suggest that the anxiolytic-like effects of 8-OH-DPAT, but not the anxiogenic-like effects of buspirone, on the elevated plus-maze are mediated via 5-HT(1A) receptors in the CNS. 8-Hydroxy-2-(di-n-propylamino)tetralin 55-64 5-hydroxytryptamine receptor 1A Homo sapiens 159-166 9218690-3 1997 [3H]8-OH-DPAT appears to bind to a single population of binding sites in both the hippocampus and the dorsal raphe nucleus, although the K(d) for the radioligand at the dorsal raphe site was five times that observed at the hippocampal 5-HT1A receptor. 8-Hydroxy-2-(di-n-propylamino)tetralin 4-13 5-hydroxytryptamine receptor 1A Homo sapiens 235-250 9218690-4 1997 Similarly, although 5-HT and selective 5-HT1A receptor ligands displayed high affinity for the [3H]8-OH-DPAT binding site in the dorsal raphe nucleus, the affinity at the dorsal raphe site was less than that observed at the hippocampal 5-HT1A receptor. 8-Hydroxy-2-(di-n-propylamino)tetralin 99-108 5-hydroxytryptamine receptor 1A Homo sapiens 39-54 9218690-8 1997 However, addition of another putative 5HT1A receptor selective ligand, buspirone, did not alter the generation of [3H]inositol phosphates, but blocked the inhibitory effect of 8-OH-DPAT on phosphoinositide hydrolysis. 8-Hydroxy-2-(di-n-propylamino)tetralin 176-185 5-hydroxytryptamine receptor 1A Homo sapiens 38-52 9218690-9 1997 These studies demonstrate that the 8-OH-DPAT binding site in the dorsal raphe nucleus displays a binding profile which is similar to the hippocampal 5-HT1A receptor, but unlike this 5-HT1A receptor the binding site in the dorsal raphe nucleus is negatively coupled to phosphoinositide turnover. 8-Hydroxy-2-(di-n-propylamino)tetralin 35-44 5-hydroxytryptamine receptor 1A Homo sapiens 149-164 9218690-9 1997 These studies demonstrate that the 8-OH-DPAT binding site in the dorsal raphe nucleus displays a binding profile which is similar to the hippocampal 5-HT1A receptor, but unlike this 5-HT1A receptor the binding site in the dorsal raphe nucleus is negatively coupled to phosphoinositide turnover. 8-Hydroxy-2-(di-n-propylamino)tetralin 35-44 5-hydroxytryptamine receptor 1A Homo sapiens 182-197 9152998-7 1997 Using [3H]WAY-100635, we confirmed an increase of 5-HT1A receptor binding sites in the frontal cortex in schizophrenia, previously demonstrated with [3H]8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 153-162 5-hydroxytryptamine receptor 1A Homo sapiens 50-65 9203529-1 1997 The effects of gender, aging and gender x age on the binding of the 5-HT1A receptor high-affinity agonist [3H]8-hydroxy-2(di-N-propylamino)tetralin ([3H]8-OH-DPAT), were evaluated and compared in tissues of human prefrontal, temporal, parietal, occipital cortex and hippocampus obtained from 21 autopsy subjects. 8-Hydroxy-2-(di-n-propylamino)tetralin 149-162 5-hydroxytryptamine receptor 1A Homo sapiens 68-83 9163561-3 1997 Tests for generalization and antagonism showed that compounds with agonistic action at the 5-HT1A receptor, such as 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin), buspirone and ipsapirone all substituted for the flesinoxan cue. 8-Hydroxy-2-(di-n-propylamino)tetralin 116-125 5-hydroxytryptamine receptor 1A Homo sapiens 91-106 9163561-3 1997 Tests for generalization and antagonism showed that compounds with agonistic action at the 5-HT1A receptor, such as 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin), buspirone and ipsapirone all substituted for the flesinoxan cue. 8-Hydroxy-2-(di-n-propylamino)tetralin 127-165 5-hydroxytryptamine receptor 1A Homo sapiens 91-106 9164586-2 1997 Pretreatment with p-MPPI reduced or blocked the effect of the 5-HT1A receptor agonist 8-OH-DPAT on two responses mediated by postsynaptic 5-HT1A receptors, reduction of body temperature and the 5-HT behavioral syndrome. 8-Hydroxy-2-(di-n-propylamino)tetralin 86-95 5-hydroxytryptamine receptor 1A Homo sapiens 62-77 9164586-2 1997 Pretreatment with p-MPPI reduced or blocked the effect of the 5-HT1A receptor agonist 8-OH-DPAT on two responses mediated by postsynaptic 5-HT1A receptors, reduction of body temperature and the 5-HT behavioral syndrome. 8-Hydroxy-2-(di-n-propylamino)tetralin 86-95 5-hydroxytryptamine receptor 1A Homo sapiens 62-68 9164586-4 1997 Pretreatment with p-MPPI also blocked the ability of 8-OH-DPAT to reduce extracellular 5-HT in the striatum, a response mediated by presynaptic 5-HT1A receptors in the dorsal raphe nucleus, but did not alter striatal 5-HT when administered alone. 8-Hydroxy-2-(di-n-propylamino)tetralin 53-62 5-hydroxytryptamine receptor 1A Homo sapiens 144-150 9105876-3 1997 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)-induced temperature reduction, lower lip retraction and tail flick responses are widely used models of 5-HT1A receptor function. 8-Hydroxy-2-(di-n-propylamino)tetralin 0-38 5-hydroxytryptamine receptor 1A Homo sapiens 154-169 9105876-3 1997 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)-induced temperature reduction, lower lip retraction and tail flick responses are widely used models of 5-HT1A receptor function. 8-Hydroxy-2-(di-n-propylamino)tetralin 40-49 5-hydroxytryptamine receptor 1A Homo sapiens 154-169 9152998-10 1997 First, they indicate that the elevated [3H]8-OH-DPAT binding seen in the same cases is attributable to an increase of 5-HT1A receptors rather than any other binding site. 8-Hydroxy-2-(di-n-propylamino)tetralin 43-52 5-hydroxytryptamine receptor 1A Homo sapiens 118-124 9152998-11 1997 Second, the enhanced [3H]8-OH-DPAT binding in schizophrenia reflects an increased density of 5-HT1A receptors, not an increased percentage of 5-HT1A receptors which are G-protein-coupled. 8-Hydroxy-2-(di-n-propylamino)tetralin 25-34 5-hydroxytryptamine receptor 1A Homo sapiens 93-99 9037397-5 1997 The labeling of human 5-HT1A receptors with [3H]WAY-100635 was antagonised by the addition of 5-HT1A receptor ligands, 5-HT, buspirone, pindolol or 8-OH-DPAT (10 microM), leaving a very low background of non-specific binding. 8-Hydroxy-2-(di-n-propylamino)tetralin 148-157 5-hydroxytryptamine receptor 1A Homo sapiens 22-28 9067310-4 1997 In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites. 8-Hydroxy-2-(di-n-propylamino)tetralin 28-37 5-hydroxytryptamine receptor 1A Homo sapiens 71-77 9067310-4 1997 In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites. 8-Hydroxy-2-(di-n-propylamino)tetralin 28-37 5-hydroxytryptamine receptor 1A Homo sapiens 205-211 9105961-1 1997 5-HT1A receptor binding sites were measured, by saturation binding with [3H]8-OH-DPAT, in frontal and occipital cortex, hippocampus and amygdala obtained at post-mortem examination from suicide victims with a firm retrospective diagnosis of depression, and matched controls. 8-Hydroxy-2-(di-n-propylamino)tetralin 76-85 5-hydroxytryptamine receptor 1A Homo sapiens 0-15 9017662-4 1997 The pharmacological profile of the [3H]8-OH-DPAT binding sites was consistent with the labelling of the 5-HT1A receptor in the hippocampus and cortex, whereas the striatal site shared strong similarity to the presynaptic serotonin transporter. 8-Hydroxy-2-(di-n-propylamino)tetralin 39-48 5-hydroxytryptamine receptor 1A Homo sapiens 104-119 9067310-19 1997 Finally, VTA neurones are stimulated by (+)-8-OH-DPAT via 5-HT1A receptors and inhibited by (-)-8-OH-DPAT via hD3 and/or hD2 receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 40-53 5-hydroxytryptamine receptor 1A Homo sapiens 58-64 9037397-5 1997 The labeling of human 5-HT1A receptors with [3H]WAY-100635 was antagonised by the addition of 5-HT1A receptor ligands, 5-HT, buspirone, pindolol or 8-OH-DPAT (10 microM), leaving a very low background of non-specific binding. 8-Hydroxy-2-(di-n-propylamino)tetralin 148-157 5-hydroxytryptamine receptor 1A Homo sapiens 22-37 9421130-11 1997 In 24FD pigeons, the 5-HT1a agonist 8-OH-DPAT (30.5 nmol) induced strong dipsogenic effects, as well as increase in food intake duration. 8-Hydroxy-2-(di-n-propylamino)tetralin 36-45 5-hydroxytryptamine receptor 1A Homo sapiens 21-27 9048968-1 1997 The ligand binding characteristics of the recombinant human 5-HT1A receptor stably expressed in a Chinese Hamster Ovary (CHO) cell line are described using a selective agonist, [3H]8-OH-DPAT, and a novel antagonist radioligand, [3H]WAY-100635. 8-Hydroxy-2-(di-n-propylamino)tetralin 181-190 5-hydroxytryptamine receptor 1A Homo sapiens 60-75 9048968-7 1997 Furthermore, [3H] 8-OH-DPAT labelled approximately 53-61% of total 5-HT1A sites recognised by [3H]WAY-100635. 8-Hydroxy-2-(di-n-propylamino)tetralin 18-27 5-hydroxytryptamine receptor 1A Homo sapiens 67-73 9048968-8 1997 The competition binding profiles of [3H]WAY-100635 and [3H]8-OH-DPAT were highly correlated and consistent with the recognition of 5-HT1A receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 59-68 5-hydroxytryptamine receptor 1A Homo sapiens 131-137 9048968-10 1997 A significant correlation between the respective affinities of a range of agonists and antagonists at recombinant human and rodent hippocampal 5-HT1A binding sites (previously published) was also observed using [3H]WAY-100635 (r = 0.92; P < 0.0005) and [3H]8-OH-DPAT (r = 0.96; P < 0.0005). 8-Hydroxy-2-(di-n-propylamino)tetralin 260-269 5-hydroxytryptamine receptor 1A Homo sapiens 143-149 9016944-3 1996 Dose-effect curves obtained by simultaneously applying equipotent concentrations of the selective 5-HT1A agonist 8-OH-DPAT and the selective 5-HT1D receptor agonist sumatriptan are shifted to the right, although maximal effects are additive. 8-Hydroxy-2-(di-n-propylamino)tetralin 113-122 5-hydroxytryptamine receptor 1A Homo sapiens 98-104 8819496-7 1996 Pretreatment of P11-5HT1A cells with the phorbol ester, phorbol 12-myristate 13-acetate (PMA), also resulted in desensitization of the 5-HT1A receptor, as indicated by a marked decrease in the potency and intrinsic activity of 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 227-236 5-hydroxytryptamine receptor 1A Homo sapiens 135-150 8923668-5 1996 The specific binding of the radioligand in the hippocampal region, an area rich in 5-HT1A receptor density, was blocked by a chasing dose of (+/-) 8-OH-DPAT (2 mg/kg, i.v.) 8-Hydroxy-2-(di-n-propylamino)tetralin 147-156 5-hydroxytryptamine receptor 1A Homo sapiens 83-98 9085496-5 1996 Both CGS-12066 and 8-OH-DPAT (5HT1B and 5HT1A receptor agonists, respectively) suppressed XII nerve activity in a dose-dependent manner by about 20%. 8-Hydroxy-2-(di-n-propylamino)tetralin 19-28 5-hydroxytryptamine receptor 1A Homo sapiens 40-54 8798386-3 1996 Activation of ERK2 by the 5-HT1A receptor-selective agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by pertussis toxin and substantially by prolonged treatment of cells with phorbol 12-myristate 13-acetate. 8-Hydroxy-2-(di-n-propylamino)tetralin 60-111 5-hydroxytryptamine receptor 1A Homo sapiens 26-41 8798386-3 1996 Activation of ERK2 by the 5-HT1A receptor-selective agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by pertussis toxin and substantially by prolonged treatment of cells with phorbol 12-myristate 13-acetate. 8-Hydroxy-2-(di-n-propylamino)tetralin 113-122 5-hydroxytryptamine receptor 1A Homo sapiens 26-41 8865198-4 1996 The current (dose)-dependent inhibition produced by the serotonin agonists did not differ significantly from the inhibition produced by MDMA except for the 5-HT1A agonist 8-hydroxy-(2-di-n-propylamino) tetralin, which inhibited glutamate-evoked firing significantly more than MDMA or any of the other serotonin agonists. 8-Hydroxy-2-(di-n-propylamino)tetralin 171-210 5-hydroxytryptamine receptor 1A Homo sapiens 156-162 11224433-6 1996 We also found that three doses of the 5-HT(1A) agonist, 8-OH-DPAT, caused a biphasic dose effect on impulsivity. 8-Hydroxy-2-(di-n-propylamino)tetralin 56-65 5-hydroxytryptamine receptor 1A Homo sapiens 38-45 8841890-2 1996 A high density of 5-HT1A receptors, labeled by [3H]8-hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT), was found in the superficial layers of the dorsal horn, with a significant enrichment ( approximately 20%) in the lumbar vs. the thoracic and cervical segments. 8-Hydroxy-2-(di-n-propylamino)tetralin 91-104 5-hydroxytryptamine receptor 1A Homo sapiens 18-24 9162203-0 1996 Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. 8-Hydroxy-2-(di-n-propylamino)tetralin 25-34 5-hydroxytryptamine receptor 1A Homo sapiens 56-63 9162203-2 1996 In view of the evidence that one serotonin (5-HT) receptor, the 5-HT(1A) subtype, is associated with cortical glutamatergic neurons, we have used quantitative receptor autoradiography to measure the specific binding of the 5-HT(1A) receptor ligand [3H]8-OH-DPAT (2 nM) in sections of orbital frontal cortex taken from 18 control and 12 schizophrenic postmortem brains. 8-Hydroxy-2-(di-n-propylamino)tetralin 252-261 5-hydroxytryptamine receptor 1A Homo sapiens 64-71 9162203-2 1996 In view of the evidence that one serotonin (5-HT) receptor, the 5-HT(1A) subtype, is associated with cortical glutamatergic neurons, we have used quantitative receptor autoradiography to measure the specific binding of the 5-HT(1A) receptor ligand [3H]8-OH-DPAT (2 nM) in sections of orbital frontal cortex taken from 18 control and 12 schizophrenic postmortem brains. 8-Hydroxy-2-(di-n-propylamino)tetralin 252-261 5-hydroxytryptamine receptor 1A Homo sapiens 223-240 8632301-3 1996 The 5-HT1A agonists, buspirone and 8-OH-DPAT, which lack affinity for 5-HT2A/2C receptors, produced dose-related increases in punished responding. 8-Hydroxy-2-(di-n-propylamino)tetralin 35-44 5-hydroxytryptamine receptor 1A Homo sapiens 4-10 8801608-4 1996 With 5-HT agonists, 8-OH-DPAT (5-HT1A) suppressed the two oral stereotypies and increased standing (all 1.0 mg/kg) and preening (0.2 mg/kg), alpha-methylserotonin (5-HT2) suppressed the oral stereotypies and increased sitting (all 1.0 mg/kg), and m-CPBG (5-HT3) suppressed drinker-directed activity (1.0 mg/kg). 8-Hydroxy-2-(di-n-propylamino)tetralin 20-29 5-hydroxytryptamine receptor 1A Homo sapiens 31-37 8882616-7 1996 The 5-HT1A receptor agonist, (+/-)-8-hydroxy-2-(di-n-propylamino) tetraline (8-OH-DPAT) (10 to 3000 nM) induced a concentration-dependent increase (P < 0.05) in Na+, K(+)-ATPase activity with an EC50 value of 355 nM (95% confidence limits: 178, 708). 8-Hydroxy-2-(di-n-propylamino)tetralin 77-86 5-hydroxytryptamine receptor 1A Homo sapiens 4-19 8882616-8 1996 Maximal stimulation elicited by 3000 nM of 8-OH-DPAT was antagonized by the selective 5-HT1A receptor antagonist, (+)-WAY 100135 10 to 1000 nM) with an IC50 value of 20 nM (14, 29); 0.3 microM (+)-WAY 100135 completely abolished (P < 0.01) the stimulatory effect of 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 43-52 5-hydroxytryptamine receptor 1A Homo sapiens 86-101 8882616-8 1996 Maximal stimulation elicited by 3000 nM of 8-OH-DPAT was antagonized by the selective 5-HT1A receptor antagonist, (+)-WAY 100135 10 to 1000 nM) with an IC50 value of 20 nM (14, 29); 0.3 microM (+)-WAY 100135 completely abolished (P < 0.01) the stimulatory effect of 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 269-278 5-hydroxytryptamine receptor 1A Homo sapiens 86-101 9005436-5 1996 The simulations indicated that the 5-HT(1a) receptor agonists, (R)- and (S)-8-OH-DPAT and (R)-UH-301, interacted with the receptor at a site closer to Asp82 in TMH2 than did (S)-UH-301, which is a 5-HT1a receptor antagonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 72-85 5-hydroxytryptamine receptor 1A Homo sapiens 35-52 9005436-1 1996 A three-dimensional model of the human 5-HT(1a) receptor was constructed by molecular modelling, and the molecular and electronic structures of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin (UH-301) and of (R)- and (S)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) were examined by molecular mechanics and quantum mechanics calculations and molecular dynamics simulations. 8-Hydroxy-2-(di-n-propylamino)tetralin 268-277 5-hydroxytryptamine receptor 1A Homo sapiens 39-56 9005436-3 1996 Interactions of UH-301 and 8-OH-DPAT with the 5-HT(1a) receptor were examined by molecular dynamics simulations and energy minimization of receptor-ligand complexes. 8-Hydroxy-2-(di-n-propylamino)tetralin 27-36 5-hydroxytryptamine receptor 1A Homo sapiens 46-63 9005436-5 1996 The simulations indicated that the 5-HT(1a) receptor agonists, (R)- and (S)-8-OH-DPAT and (R)-UH-301, interacted with the receptor at a site closer to Asp82 in TMH2 than did (S)-UH-301, which is a 5-HT1a receptor antagonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 72-85 5-hydroxytryptamine receptor 1A Homo sapiens 197-212 8788510-5 1996 An interesting finding was that blockade [3H]5-CT binding to 5-HT1A receptors by 8-OH-DPAT could only be achieved at very high concentrations of the displacer. 8-Hydroxy-2-(di-n-propylamino)tetralin 81-90 5-hydroxytryptamine receptor 1A Homo sapiens 61-67 8551355-7 1996 After abolishing the crossed IPSPs by spinal transection, systemic administration of the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT; 0.1-1.3 mg/kg, i.v.) 8-Hydroxy-2-(di-n-propylamino)tetralin 113-170 5-hydroxytryptamine receptor 1A Homo sapiens 89-104 9328612-3 1996 In the second study we have compared the effectiveness of intracerebroventricular and intravenous administration of 8-OH-DPAT in frequently used behavioural models of 5-HT1A receptor activation, namely lower lip retraction, body temperature and tail flick responses. 8-Hydroxy-2-(di-n-propylamino)tetralin 116-125 5-hydroxytryptamine receptor 1A Homo sapiens 167-182 9328615-2 1996 WAY 100635 selectively blocked 5-HT1A receptor-mediated responses of 5-HT, 8-OH-DPAT, lesopitron and 5-CT. 8-Hydroxy-2-(di-n-propylamino)tetralin 75-84 5-hydroxytryptamine receptor 1A Homo sapiens 31-46 7562940-4 1995 All compounds showed high affinity at 5-HT1A sites (8.10 < or = pKis < or = 9.35), and the majority behaved as antagonists in vivo in blocking the hypothermia induced by the 5-HT1A agonist 8-OH-DPAT in the absence of a marked effect alone at equivalent doses. 8-Hydroxy-2-(di-n-propylamino)tetralin 195-204 5-hydroxytryptamine receptor 1A Homo sapiens 38-44 8566173-2 1995 We now report that the 5-HT1A receptor agonist R(+)-8-hydroxy-2-(di-n- propylamino)tetralin (8-OH-DPAT) is also capable of stimulating [3H]thymidine incorporation into SCLC GLC-8 cells, although with lower efficacy than 5-HT. 8-Hydroxy-2-(di-n-propylamino)tetralin 93-102 5-hydroxytryptamine receptor 1A Homo sapiens 23-38 8566173-4 1995 The 5-HT1A receptor antagonists spiperone and SDZ 216-525 completely abolished the effect of 8-OH-DPAT (IC50 30 nM for both drugs) behaving as pure antagonists. 8-Hydroxy-2-(di-n-propylamino)tetralin 93-102 5-hydroxytryptamine receptor 1A Homo sapiens 4-19 7671319-5 1995 Spiperone and NAN-190, antagonists to 5-HT1A receptor subtype, abolished the serotonin effects on calcium signaling, whereas an agonist to 5-HT1A receptor, 8OHDPAT, mimicked the serotonin-like action on the diminution of the intracellular calcium contents. 8-Hydroxy-2-(di-n-propylamino)tetralin 156-163 5-hydroxytryptamine receptor 1A Homo sapiens 139-154 8979820-3 1996 Autoradiography of tissue sections exposed to [3H]-8-OH-DPAT (8-hydroxy-dipropylaminotetraline) or to [125I]cyanopindolol plus isoproterenol showed that 5-HT1A and 5-HT1B receptors, respectively, were present in the superficial SC layers. 8-Hydroxy-2-(di-n-propylamino)tetralin 51-60 5-hydroxytryptamine receptor 1A Homo sapiens 153-159 8742464-2 1995 In the present study the CCKA receptor antagonist devazepide (50-200 micrograms kg-1, s.c.) was found reliably to potentiate the feeding response elicited by dorsal or median raphe injection of the 5-HT1A agonist 8-OH-DPAT (0.2-0.8 nmol). 8-Hydroxy-2-(di-n-propylamino)tetralin 213-222 5-hydroxytryptamine receptor 1A Homo sapiens 198-204 8524978-6 1995 The 5HT1A agonist 8-OH-DPAT produced drug-appropriate responding at higher doses (0.3-1.0 mg/kg), whereas much lower doses (0.003-1.0 mg/kg) antagonized the methamphetamine stimulus. 8-Hydroxy-2-(di-n-propylamino)tetralin 18-27 5-hydroxytryptamine receptor 1A Homo sapiens 4-9 8539333-2 1995 5-HT1A receptors have been cloned and a variety of selective agonists, such as the aminotetraline 8-OH-DPAT and the pyrimidinylpiperazine ipsapirone, have become available. 8-Hydroxy-2-(di-n-propylamino)tetralin 98-107 5-hydroxytryptamine receptor 1A Homo sapiens 0-6 7540664-5 1995 Preincubation of transfected HeLa cell membranes with Ab-2 antibodies revealed two affinity binding sites of the 5-HT1A receptor (KDH = 0.54 +/- 0.09 nM and KDL = 13.74 +/- 4.9 nM) for the agonist 8-hydroxy-2-(di-n-[3H]propylamino) tetralin ([3H]8-OH-DPAT) binding, but Ab-1 and Ab-12 revealed only one site (KD of approximately 2.5 nM). 8-Hydroxy-2-(di-n-propylamino)tetralin 242-255 5-hydroxytryptamine receptor 1A Homo sapiens 113-128 7662151-2 1995 The 5-HT1A agonist 8-OH-DPAT was microinjected into the region of the DRN either before exposure to IS or before testing for fear conditioning and escape learning conducted 24 hr later. 8-Hydroxy-2-(di-n-propylamino)tetralin 19-28 5-hydroxytryptamine receptor 1A Homo sapiens 4-10 7566497-4 1995 The BMY7378- and 8-OH-DPAT-induced inhibition of 5-HT release were reversed by a 40 min pre-treatment with either (+/-)pindolol (8 mg/kg, s.c.) or WAY-100635 (0.3 mg/kg, s.c.), to block 5-HT1A autoreceptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 17-26 5-hydroxytryptamine receptor 1A Homo sapiens 186-192 7608342-2 1995 The 5-HT1A receptor has been shown to mediate motoneuron responses in spinal reflex pathways using the highly selective 5-HT1A receptor agonist 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 144-153 5-hydroxytryptamine receptor 1A Homo sapiens 4-19 7608342-2 1995 The 5-HT1A receptor has been shown to mediate motoneuron responses in spinal reflex pathways using the highly selective 5-HT1A receptor agonist 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 144-153 5-hydroxytryptamine receptor 1A Homo sapiens 120-135 7667330-6 1995 Further, a correlation analysis across each of the above agonists, as well as 8-OH-DPAT, buspirone, and (+)-flesinoxan, revealed a significant correlation for their relative potency in augmenting punished responding and their affinity for 5-HT1A receptors in vitro (r = +0.95, p < 0.001). 8-Hydroxy-2-(di-n-propylamino)tetralin 78-87 5-hydroxytryptamine receptor 1A Homo sapiens 239-245 7777653-5 1995 The 5-HT1A agonist, 8-OH-DPAT, was able to attenuate the adrenocortical responses to acoustic stimulation, conditioned fear, IL-1 alpha, and cocaine administration, with ipsapirone also being effective in reducing the responses to acoustic stimulation and cocaine injection. 8-Hydroxy-2-(di-n-propylamino)tetralin 20-29 5-hydroxytryptamine receptor 1A Homo sapiens 4-10 7705452-9 1994 Substantial (77%) blockade of [3H]WAY-100635 binding was achieved with the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), and the partial agonists, ipsapirone and buspirone. 8-Hydroxy-2-(di-n-propylamino)tetralin 140-149 5-hydroxytryptamine receptor 1A Homo sapiens 75-81 7550544-0 1995 Attenuation of the fentanyl-induced muscle rigidity by the selective 5HT1A agonist 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 83-92 5-hydroxytryptamine receptor 1A Homo sapiens 69-74 7550544-2 1995 The selective 5HT1A receptor agonist 8-OH-DPAT (0.1, 0.3 and 1.0 mg/kg ip) showed only a tendency to attenuate the natural muscle tone. 8-Hydroxy-2-(di-n-propylamino)tetralin 37-46 5-hydroxytryptamine receptor 1A Homo sapiens 14-28 7886629-6 1994 The specific binding of the radioligand in the hippocampal region, an area rich in 5-HT1A receptor density, was blocked by pretreatment with a dose of (+/-) 8-OH-DPAT (2 mg/kg, i.v.) 8-Hydroxy-2-(di-n-propylamino)tetralin 157-166 5-hydroxytryptamine receptor 1A Homo sapiens 83-98 7855734-0 1994 5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. 8-Hydroxy-2-(di-n-propylamino)tetralin 18-27 5-hydroxytryptamine receptor 1A Homo sapiens 0-6 7824554-3 1994 Both the unconditioned and conditioned emetic responses were dose-dependently blocked by 8-hydroxy-(di-n-propylamino)tetralin (8-OH-DPAT) and LY228729, agonists at the 5-HT1A subtype of serotonin receptor, but not by the 5-HT3, antagonist tropisetron. 8-Hydroxy-2-(di-n-propylamino)tetralin 127-136 5-hydroxytryptamine receptor 1A Homo sapiens 168-174 7824554-5 1994 NAN-190, a putative 5-HT1A partial agonist, produced both an antiemetic response when administered before DTG and also attenuated the antiemetic effects of 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 156-165 5-hydroxytryptamine receptor 1A Homo sapiens 20-26 7993956-7 1994 In conclusion, the present results confirm our previous results using 8-OH-DPAT as a challenge, and suggest that chronic 5-HT uptake inhibition results in adaptive changes leading to decreased function of the 5-HT1A receptor system. 8-Hydroxy-2-(di-n-propylamino)tetralin 70-79 5-hydroxytryptamine receptor 1A Homo sapiens 209-224 7834355-3 1994 The expression study revealed that 5HT1A mRNA distribution in the hippocampus and prefrontal cortex was consistent with the data of the [3H]8-OH-DPAT binding. 8-Hydroxy-2-(di-n-propylamino)tetralin 140-149 5-hydroxytryptamine receptor 1A Homo sapiens 35-40 7820591-4 1994 injection of the 5-HT1A receptor agonist, 8-OH-DPAT, during the dark phase (6 h after lights-off) significantly reduced the extracellular glutamate concentration in the SCN region from baseline levels (38.7 +/- 8.7 and 53.4 +/- 11.2%, respectively, of pretreatment values; P < 0.05). 8-Hydroxy-2-(di-n-propylamino)tetralin 42-51 5-hydroxytryptamine receptor 1A Homo sapiens 17-32 7862933-4 1994 In drug discrimination studies, pigeons were trained to discriminate injections of the 5-HT1A agonist 8-OH-DPAT (0.3 mg/kg) from saline. 8-Hydroxy-2-(di-n-propylamino)tetralin 102-111 5-hydroxytryptamine receptor 1A Homo sapiens 87-93 7862933-9 1994 All compounds substituted for 8-OH-DPAT in the drug discrimination procedure, suggestive of 5-HT1A agonist activity. 8-Hydroxy-2-(di-n-propylamino)tetralin 30-39 5-hydroxytryptamine receptor 1A Homo sapiens 92-98 7548638-5 1994 Also the selectivity of 8-OH-DPAT for the 5-HT1A receptor is accounted for. 8-Hydroxy-2-(di-n-propylamino)tetralin 24-33 5-hydroxytryptamine receptor 1A Homo sapiens 42-57 7988650-3 1994 At 25 micrograms/kg, 8-hydroxy-2-(di-n-propylamino)tetralin, an agonist at 5-HT1A receptors, reduced cortical 5-HT output in controls but not in animals treated chronically with citalopram whereas 50 micrograms/kg reduced 5-HT output in both groups. 8-Hydroxy-2-(di-n-propylamino)tetralin 21-59 5-hydroxytryptamine receptor 1A Homo sapiens 75-81 8021490-9 1994 Inhibition by metitepine is reversed by 5HT and by the selective 5HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 121-130 5-hydroxytryptamine receptor 1A Homo sapiens 65-79 7522172-0 1994 Intracisternally injected galanin-(1-15) modulates the cardiovascular responses of galanin-(1-29) and the 5-HT1A receptor agonist 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 130-139 5-hydroxytryptamine receptor 1A Homo sapiens 106-121 8101137-1 1993 This study examined the effects of kainic acid and NMDA microinjections into the lateral tegmental field on the sympatholytic effect of the 5-HT1A agonist 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 155-164 5-hydroxytryptamine receptor 1A Homo sapiens 140-146 8200427-1 1994 The purpose of this study was to determine the effects of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-N-propylamino)tetralin hydrobromide (8-OH-DPAT), on respiratory activity (phrenic nerve activity) following application to the ventral medullary surface in the cat. 8-Hydroxy-2-(di-n-propylamino)tetralin 87-138 5-hydroxytryptamine receptor 1A Homo sapiens 62-77 8200427-1 1994 The purpose of this study was to determine the effects of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-N-propylamino)tetralin hydrobromide (8-OH-DPAT), on respiratory activity (phrenic nerve activity) following application to the ventral medullary surface in the cat. 8-Hydroxy-2-(di-n-propylamino)tetralin 140-149 5-hydroxytryptamine receptor 1A Homo sapiens 62-77 8008244-4 1994 Because pindolol blocked the effect of 5-HT and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) mimicked the effect of 5-HT, the inhibitory effect of 5-HT appeared to be mediated via the 5-HT1A receptor. 8-Hydroxy-2-(di-n-propylamino)tetralin 88-97 5-hydroxytryptamine receptor 1A Homo sapiens 190-205 8199864-7 1994 Treatment with the 5-HT1A receptor antagonist, NAN-190, administered 15 min before 8-OH-DPAT injection prevented the inhibitory effect of 8-OH-DPAT (100.9 +/- 6.0% vs. controls, P > 0.9). 8-Hydroxy-2-(di-n-propylamino)tetralin 83-92 5-hydroxytryptamine receptor 1A Homo sapiens 19-34 8199864-7 1994 Treatment with the 5-HT1A receptor antagonist, NAN-190, administered 15 min before 8-OH-DPAT injection prevented the inhibitory effect of 8-OH-DPAT (100.9 +/- 6.0% vs. controls, P > 0.9). 8-Hydroxy-2-(di-n-propylamino)tetralin 138-147 5-hydroxytryptamine receptor 1A Homo sapiens 19-34 8199879-2 1994 After masking 5-HT1A receptors by 0.1 microM 8-OH-DPAT, the binding displaced by 0.1 microM 5-CT presumably represented 5-HT1D sites and the remaining binding 5-HT1E sites. 8-Hydroxy-2-(di-n-propylamino)tetralin 45-54 5-hydroxytryptamine receptor 1A Homo sapiens 14-20 8005619-9 1993 Since no known cell line contains the serotonin 5-HT1A receptor (5-HT1A-R), stable transfection of the selected cell lines with a DNA construct encoding the human 5-HT1A-R was carried out and this resulted in a late increase of [3H] 8-OH-DPAT binding in the stationary phase only in the cell lines of neural origin. 8-Hydroxy-2-(di-n-propylamino)tetralin 233-242 5-hydroxytryptamine receptor 1A Homo sapiens 163-171 8138923-1 1994 Exposure of HeLa cells stably expressing cloned human 5-hydroxytryptamine (5-HT)1A receptors (HA7 cells) to the agonist 8-hydroxy-2-(di-N-propylamino)-tetralin (8-OH-DPAT) results in a loss of high-affinity binding sites and a desensitization of receptor-adenylate cyclase coupling, as measured by 5-HT1A-mediated inhibition of forskolin-stimulated adenylate cyclase activity. 8-Hydroxy-2-(di-n-propylamino)tetralin 120-159 5-hydroxytryptamine receptor 1A Homo sapiens 298-304 8301575-4 1994 The spontaneous tail-flicks, flat-body posture and hypothermia mediated by an action of the 5-HT1A agonist 8-OH-DPAT at postsynaptic 5-HT1A receptors were dose-dependently and completely antagonized by S 14489, S 15535 and S15931 at doses of 0.63 to 10.0 and 2.5 to 40.0 mg/kg for s.c. and oral administration, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 107-116 5-hydroxytryptamine receptor 1A Homo sapiens 92-98 8301575-4 1994 The spontaneous tail-flicks, flat-body posture and hypothermia mediated by an action of the 5-HT1A agonist 8-OH-DPAT at postsynaptic 5-HT1A receptors were dose-dependently and completely antagonized by S 14489, S 15535 and S15931 at doses of 0.63 to 10.0 and 2.5 to 40.0 mg/kg for s.c. and oral administration, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 107-116 5-hydroxytryptamine receptor 1A Homo sapiens 133-139 8490207-12 1993 Next we found that the 5-HT1A agonist 8-OH-DPAT, and to a lesser extent the 5-HT1A-1B agonist RU 24969, mimicked the effects of quipazine during the subjective daytime, whereas the 5-HT1A antagonist NAN-190 blocked quipazine"s effects. 8-Hydroxy-2-(di-n-propylamino)tetralin 38-47 5-hydroxytryptamine receptor 1A Homo sapiens 23-29 8098761-8 1993 Furthermore, (-)penbutolol, but not its (+)antipode, prevented the decrease of 5-HT release induced by the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin. 8-Hydroxy-2-(di-n-propylamino)tetralin 131-175 5-hydroxytryptamine receptor 1A Homo sapiens 107-122 8459396-12 1993 Overall, the SAR study showed that cis C-1 substitution maintains the 5-HT1A agonist activity of 8-OH-DPAT whereas trans C-1 substitution displays somewhat diminished activity. 8-Hydroxy-2-(di-n-propylamino)tetralin 97-106 5-hydroxytryptamine receptor 1A Homo sapiens 70-76 8497336-7 1993 These effects were similar to those produced by the tricyclic antidepressant desipramine and the 5-HT1A agonist 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 112-121 5-hydroxytryptamine receptor 1A Homo sapiens 97-103 8389958-7 1993 Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered. 8-Hydroxy-2-(di-n-propylamino)tetralin 37-75 5-hydroxytryptamine receptor 1A Homo sapiens 13-28 8461029-4 1993 For both radioligands the binding sites labelled have the properties of 5HT1A receptors and most antagonists show roughly equal affinities for the receptors labelled by either [3H]8-OH-DPAT or [3H]spiperone. 8-Hydroxy-2-(di-n-propylamino)tetralin 180-189 5-hydroxytryptamine receptor 1A Homo sapiens 72-77 8389958-7 1993 Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered. 8-Hydroxy-2-(di-n-propylamino)tetralin 77-86 5-hydroxytryptamine receptor 1A Homo sapiens 13-28 8430834-13 1993 Radioligand binding studies with the specific 5-HT1A receptor ligand [3H]8-OH-DPAT confirmed the presence of 5-HT1A receptor binding sites in bulk-isolated rat medullary TAL. 8-Hydroxy-2-(di-n-propylamino)tetralin 73-82 5-hydroxytryptamine receptor 1A Homo sapiens 46-61 8382063-4 1993 Full inhibition was observed with 5-HT1A receptor agonists: N,N-dipropyl-8-hydroxy-2-aminotetralin (8-OH-DPAT) and flesinoxan, and non-selective 5-HT receptor agonists: d-lysergic acid diethylamide (d-LSD), RU 24,969, bufotenine, methysergide and tryptamine. 8-Hydroxy-2-(di-n-propylamino)tetralin 100-109 5-hydroxytryptamine receptor 1A Homo sapiens 34-49 8381359-2 1993 In vivo, S 15535 (0.16-10 mg/kg s.c.) acted as an antagonist at postsynaptic 5-HT1A receptors in completely blocking the flat-body posture and hypothermia elicited by the 5-HT1A receptor agonist, 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 196-205 5-hydroxytryptamine receptor 1A Homo sapiens 77-83 8430834-13 1993 Radioligand binding studies with the specific 5-HT1A receptor ligand [3H]8-OH-DPAT confirmed the presence of 5-HT1A receptor binding sites in bulk-isolated rat medullary TAL. 8-Hydroxy-2-(di-n-propylamino)tetralin 73-82 5-hydroxytryptamine receptor 1A Homo sapiens 109-124 1448178-2 1992 A transfected clonal cell line which expresses 900 +/- 36 fmol 5-HT1A receptor/mg protein (designated CHO-5-HT1A/WT-27) responded to 5-HT and/or 8-OH-DPAT by coupling to several second messenger pathways. 8-Hydroxy-2-(di-n-propylamino)tetralin 145-154 5-hydroxytryptamine receptor 1A Homo sapiens 63-78 1468487-4 1992 The compound was found to counteract, in a stereospecific fashion, not only the behavioural and hypothermic but also the in vivo 5-HT synthesis/turnover-reducing effects of the specific 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 210-248 5-hydroxytryptamine receptor 1A Homo sapiens 186-201 1426017-1 1992 The affinities of a range of antipsychotic drugs at human hippocampal 5-HT1A receptors, defined by specific [3H]8-OH-DPAT binding, were determined. 8-Hydroxy-2-(di-n-propylamino)tetralin 112-121 5-hydroxytryptamine receptor 1A Homo sapiens 70-76 1357094-6 1992 The selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin at 0.1 microM did not modify the electrically evoked release of [3H]5-HT. 8-Hydroxy-2-(di-n-propylamino)tetralin 38-76 5-hydroxytryptamine receptor 1A Homo sapiens 14-29 1436121-0 1992 Differential coupling of 5-HT1A receptors occupied by 5-HT or 8-OH-DPAT to adenylyl cyclase. 8-Hydroxy-2-(di-n-propylamino)tetralin 62-71 5-hydroxytryptamine receptor 1A Homo sapiens 25-31 1436390-0 1992 Desensitization of 5-HT1A autoreceptors by chronic administration of 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 69-78 5-hydroxytryptamine receptor 1A Homo sapiens 19-25 1436390-1 1992 The function of 5-HT1A autoreceptors was examined by measuring the ability of the 5-HT1A receptor agonist 8-OH-DPAT to reduce 5-HT release in the striatum using in vivo microdialysis. 8-Hydroxy-2-(di-n-propylamino)tetralin 106-115 5-hydroxytryptamine receptor 1A Homo sapiens 16-22 1436390-1 1992 The function of 5-HT1A autoreceptors was examined by measuring the ability of the 5-HT1A receptor agonist 8-OH-DPAT to reduce 5-HT release in the striatum using in vivo microdialysis. 8-Hydroxy-2-(di-n-propylamino)tetralin 106-115 5-hydroxytryptamine receptor 1A Homo sapiens 82-97 1446239-10 1992 Iontophoretic application of the 5HT1A agonists, 8-OH-DPAT and ipsapirone, mimic the suppressive action of serotonin in a dose-dependent manner. 8-Hydroxy-2-(di-n-propylamino)tetralin 49-58 5-hydroxytryptamine receptor 1A Homo sapiens 33-38 7680787-4 1993 Serotonin release was reduced by the systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 92-130 5-hydroxytryptamine receptor 1A Homo sapiens 68-83 7680787-4 1993 Serotonin release was reduced by the systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 132-141 5-hydroxytryptamine receptor 1A Homo sapiens 68-83 7870936-5 1993 During combination tests, the selective 5HT1A agonist, 8-OH-DPAT (0.001-3.2 mg/kg), dose-dependently attenuated the discriminative stimulus effects of 5.6 mg/kg U50,488 and 3.2 mg/kg spiradoline. 8-Hydroxy-2-(di-n-propylamino)tetralin 55-64 5-hydroxytryptamine receptor 1A Homo sapiens 40-45 1468487-4 1992 The compound was found to counteract, in a stereospecific fashion, not only the behavioural and hypothermic but also the in vivo 5-HT synthesis/turnover-reducing effects of the specific 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 250-259 5-hydroxytryptamine receptor 1A Homo sapiens 186-201 1387027-10 1992 BMY 7378 (8 mg kg-1, s.c.) inhibited another effect of activation of postsynaptic 5-HT1A receptors, i.e., the induction of components of the 5-HT syndrome by 8-OH-DPAT (0.5, 1.0 mg kg-1, s.c.) which suggests that BMY 7378 has antagonistic as well as agonistic effects at these sites. 8-Hydroxy-2-(di-n-propylamino)tetralin 158-167 5-hydroxytryptamine receptor 1A Homo sapiens 82-88 1448178-2 1992 A transfected clonal cell line which expresses 900 +/- 36 fmol 5-HT1A receptor/mg protein (designated CHO-5-HT1A/WT-27) responded to 5-HT and/or 8-OH-DPAT by coupling to several second messenger pathways. 8-Hydroxy-2-(di-n-propylamino)tetralin 145-154 5-hydroxytryptamine receptor 1A Homo sapiens 63-69 1316283-5 1992 The phase advance induced by 8-OH-DPAT was blocked by pretreatment with (-)-pindolol, a 5-HT1A receptor antagonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 29-38 5-hydroxytryptamine receptor 1A Homo sapiens 88-103 1356248-3 1992 Completely analogous effects were found at the somatodendritic 5-HT1A autoreceptor in the raphe nuclei, mediating inhibition of the synthesis of serotonin (5-HT); the full agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and the partial agonist, buspirone were utilized to inhibit the synthesis of 5-HT, as measured by changes in levels of L-5-hydroxytryptophan (5-HTP). 8-Hydroxy-2-(di-n-propylamino)tetralin 181-219 5-hydroxytryptamine receptor 1A Homo sapiens 63-69 1356248-3 1992 Completely analogous effects were found at the somatodendritic 5-HT1A autoreceptor in the raphe nuclei, mediating inhibition of the synthesis of serotonin (5-HT); the full agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and the partial agonist, buspirone were utilized to inhibit the synthesis of 5-HT, as measured by changes in levels of L-5-hydroxytryptophan (5-HTP). 8-Hydroxy-2-(di-n-propylamino)tetralin 221-230 5-hydroxytryptamine receptor 1A Homo sapiens 63-69 1409788-0 1992 The 5-HT1A agonist 8-OH-DPAT attenuates the satiating action of cholecystokinin. 8-Hydroxy-2-(di-n-propylamino)tetralin 19-28 5-hydroxytryptamine receptor 1A Homo sapiens 4-10 1535691-4 1992 The pharmacological profiles of the binding (determined with [3H]8-OH-DPAT) and the calcium response (measured using Fura-2) were clearly of the 5-HT1A type. 8-Hydroxy-2-(di-n-propylamino)tetralin 61-74 5-hydroxytryptamine receptor 1A Homo sapiens 145-151 1389001-2 1992 In the present study the excitatory action of nicotine was inhibited by treatment with the selective 5-HT re-uptake inhibitor citalopram or the 5-HT1A receptor agonist 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 168-177 5-hydroxytryptamine receptor 1A Homo sapiens 144-159 1531359-1 1992 The purported serotonin (5-HT)1A antagonists BMY-7378 and NAN-190 were examined in pigeons for their potential to block the effects of the prototypical 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on punished ("conflict") and unpunished behavior and for their binding affinity at the 5-HT1A receptor site labeled by [3H]-8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 167-205 5-hydroxytryptamine receptor 1A Homo sapiens 152-158 1318516-3 1992 The 5-HT1A receptor agonist, 8-OH-DPAT, and the adenyl cyclase activator, forskolin administered together, produced an additive hyperalgesia, suggesting that the 5-HT1A receptor in peripheral terminals of the primary afferent neurons is positively coupled to the cAMP second messenger system in producing hyperalgesia. 8-Hydroxy-2-(di-n-propylamino)tetralin 29-38 5-hydroxytryptamine receptor 1A Homo sapiens 162-177 1410132-5 1992 In the tail-flick analgesiometric test, administration of the 5-HT1A agonists 8-OH-DPAT and ipsapirone and the 5-HT1B agonists RU24969 and mCPP resulted in a significant dose-dependent increase in tail-flick latencies when compared to predrug baseline values, indicating a decrease in nociceptive sensitivity to noxious thermal stimuli. 8-Hydroxy-2-(di-n-propylamino)tetralin 78-87 5-hydroxytryptamine receptor 1A Homo sapiens 62-68 1667606-8 1991 The regional distribution of 5-HT1A receptors labelled by [3H]rauwolscine is in agreement with previous studies using [3H]8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 122-131 5-hydroxytryptamine receptor 1A Homo sapiens 29-35 1762063-7 1991 Drug-appropriate responding occurred in pigeons trained at the lower dose of imipramine with the 5-HT1A compounds 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide and gepirone; partial substitution occurred in pigeons trained with the higher dose of imipramine. 8-Hydroxy-2-(di-n-propylamino)tetralin 114-165 5-hydroxytryptamine receptor 1A Homo sapiens 97-103 11224080-0 1991 Modification of the discriminative stimulus effects of 8-OH-DPAT, buspirone and the beta-adrenoreceptor antagonist pindolol after chronic administration of the 5-HT(1A) agonist 8-OH-DPAT in the pigeon. 8-Hydroxy-2-(di-n-propylamino)tetralin 177-186 5-hydroxytryptamine receptor 1A Homo sapiens 160-167 11224080-6 1991 Chronic administration of 8-OH-DPAT resulted in a heightened sensitivity not only to the 5-HT(1A) agonists 8-OH-DPAT and buspirone, but also to what appear to be partial agonist effects of pindolol. 8-Hydroxy-2-(di-n-propylamino)tetralin 26-35 5-hydroxytryptamine receptor 1A Homo sapiens 89-96 11224080-6 1991 Chronic administration of 8-OH-DPAT resulted in a heightened sensitivity not only to the 5-HT(1A) agonists 8-OH-DPAT and buspirone, but also to what appear to be partial agonist effects of pindolol. 8-Hydroxy-2-(di-n-propylamino)tetralin 107-116 5-hydroxytryptamine receptor 1A Homo sapiens 89-96 11224080-7 1991 This approach represents a first step in the in vivo characterization of changes in 5-HT(1A) sensitivity after chronic administration of 8-OH-DPAT using the drug discrimination procedure. 8-Hydroxy-2-(di-n-propylamino)tetralin 137-146 5-hydroxytryptamine receptor 1A Homo sapiens 84-91 1838579-4 1991 In competition studies, the rank order of drug affinities was suggestive of a 5-HT1A binding site: 5-HT greater than 8-OH-DPAT, RU24969 greater than methysergide, methiothepin, 1-2,5-dimethoxy-4-iodophenyl aminopropane (DOI), ketanserin greater than mianserin. 8-Hydroxy-2-(di-n-propylamino)tetralin 117-126 5-hydroxytryptamine receptor 1A Homo sapiens 78-84 1819150-6 1991 In contrast, the selective 5-HT1A receptor agonists 8-OH-DPAT and flesinoxan decrease blood pressure and heart rate by a centrally-mediated decrease in sympathetic tone and an increase in vagal tone. 8-Hydroxy-2-(di-n-propylamino)tetralin 52-61 5-hydroxytryptamine receptor 1A Homo sapiens 27-42 1839567-6 1991 Both the nonselective 5-HT agonist 5-MeODMT (1.25 mg/kg) and the more selective 5-HT1A agonist 8-OH-DPAT (2 mg/kg) disrupted spontaneous alternation. 8-Hydroxy-2-(di-n-propylamino)tetralin 95-104 5-hydroxytryptamine receptor 1A Homo sapiens 80-86 1834306-1 1991 Quantitative autoradiographic analysis of serotonin 5-HT1A receptors in the human brain, using [3H]8-OH-DPAT as a ligand, reveals region-specific decreases in receptor labeling with age in several cortical and hippocampal regions and in the raphe nuclei. 8-Hydroxy-2-(di-n-propylamino)tetralin 99-108 5-hydroxytryptamine receptor 1A Homo sapiens 52-58 1664803-1 1991 The aim of the present study was to assess the effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and flesinoxan in ring preparations of human basilar artery. 8-Hydroxy-2-(di-n-propylamino)tetralin 86-124 5-hydroxytryptamine receptor 1A Homo sapiens 62-77 1664803-1 1991 The aim of the present study was to assess the effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and flesinoxan in ring preparations of human basilar artery. 8-Hydroxy-2-(di-n-propylamino)tetralin 126-135 5-hydroxytryptamine receptor 1A Homo sapiens 62-77 1664803-9 1991 We conclude from the relative rank order of antagonist potency that 8-OH-DPAT and 5-HT produce contraction of the human basilar artery by activation of the same receptor, a 5-HT1-like receptor distinct from the 5-HT1A receptor subtype. 8-Hydroxy-2-(di-n-propylamino)tetralin 68-77 5-hydroxytryptamine receptor 1A Homo sapiens 211-226 1715390-2 1991 Administration of 8-OH-DPAT, a 5-HT1A receptor agonist that decreases 5-HT neuronal activity, decreased extracellular 5-HT in both brain areas. 8-Hydroxy-2-(di-n-propylamino)tetralin 18-27 5-hydroxytryptamine receptor 1A Homo sapiens 31-46 1658007-1 1991 1 We have examined the actions of the 5-HT1A-receptor ligand 8-OH-DPAT at alpha 2-adrenoceptor ligand binding sites in human platelet and rat kidney membranes and at functional pre- and postjunctional alpha 2-adrenoceptors in rat atrium and human saphenous vein, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 61-70 5-hydroxytryptamine receptor 1A Homo sapiens 38-53 2136217-2 1990 The putative 5-HT1A receptor agonists buspirone, gepirone, ipsapirone and 8-OH-DPAT all produced anxiolytic-like effects in narrow low dose-ranges, while in higher doses the behavior returned towards that seen in controls and, after the highest doses of buspirone and gepirone, was suppressed below that of controls. 8-Hydroxy-2-(di-n-propylamino)tetralin 74-83 5-hydroxytryptamine receptor 1A Homo sapiens 13-28 1683291-7 1991 Similarly we have previously observed spiperone reversal of the sympatholytic effects of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) but failed to affect nerve activity when given alone. 8-Hydroxy-2-(di-n-propylamino)tetralin 108-117 5-hydroxytryptamine receptor 1A Homo sapiens 93-99 1683291-7 1991 Similarly we have previously observed spiperone reversal of the sympatholytic effects of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) but failed to affect nerve activity when given alone. 8-Hydroxy-2-(di-n-propylamino)tetralin 119-157 5-hydroxytryptamine receptor 1A Homo sapiens 93-99 1829231-2 1991 The selective 5-HT1A agonist 8-OH-DPAT (0.03-1.0 mg/kg) resulted in dose-dependent increases in responding on the key correlated with imipramine administration. 8-Hydroxy-2-(di-n-propylamino)tetralin 29-38 5-hydroxytryptamine receptor 1A Homo sapiens 14-20 1772068-12 1991 Hyperpolarizing responses are also elicited by the 5-HT1A agonist, 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 67-76 5-hydroxytryptamine receptor 1A Homo sapiens 51-57 1834090-1 1991 The density of 5-HT1A binding using 3H-8-hydroxy-2-(di-n-propyl-amino) tetralin (8-OH-DPAT) as binding ligand, was studied in human frontal cortex of suicide victims and normal controls who died due to medical disease or accidentally. 8-Hydroxy-2-(di-n-propylamino)tetralin 81-90 5-hydroxytryptamine receptor 1A Homo sapiens 15-21 1886079-2 1991 In our attempt to develop new agents that would interact selectively at certain 5-HT receptors, especially the 5-HT1A subtype, 8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT) served as a template for the design of novel agents sharing aspects of the pharmacophore of 8-OH-DPAT and 5-HT. 8-Hydroxy-2-(di-n-propylamino)tetralin 127-164 5-hydroxytryptamine receptor 1A Homo sapiens 111-117 1886079-2 1991 In our attempt to develop new agents that would interact selectively at certain 5-HT receptors, especially the 5-HT1A subtype, 8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT) served as a template for the design of novel agents sharing aspects of the pharmacophore of 8-OH-DPAT and 5-HT. 8-Hydroxy-2-(di-n-propylamino)tetralin 166-175 5-hydroxytryptamine receptor 1A Homo sapiens 111-117 1886079-3 1991 5-HT contains no center of asymmetry, and 8-OH-DPAT shows only very modest stereospecificity for 5-HT1A receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 42-51 5-hydroxytryptamine receptor 1A Homo sapiens 97-103 1886079-4 1991 To develop agents having enhanced potency and selectivity for the 5-HT1A site, several ring systems offering enhanced conformational rigidity which approximate the oxygen to nitrogen interatomic distances of 8-OH-DPAT and (to a lesser extent) 5-HT were synthesized. 8-Hydroxy-2-(di-n-propylamino)tetralin 208-217 5-hydroxytryptamine receptor 1A Homo sapiens 66-72 1824956-4 1991 The [3H]8-OH-DPAT bindings to the prefrontal cortex and hippocampus were potently inhibited by serotonin (IC50 = 6.3 x 10(-9) M) and 5-HT1A agonists (IC50 = 5.0 x 10(-9) - 2.3 x 10(-7) M), while other neurotransmitters, 5-HT2 and 5-HT3 related compounds did not inhibit the binding (IC50 greater than 10(-5) M). 8-Hydroxy-2-(di-n-propylamino)tetralin 8-17 5-hydroxytryptamine receptor 1A Homo sapiens 133-139 1825686-5 1991 The 5-HT1A receptor agonist 8-OH-DPAT competitively inhibited carbachol-stimulated inositol phospholipid breakdown with pA2 values of 5.78 (IMR-32) and 5.61 (SK-N-MC). 8-Hydroxy-2-(di-n-propylamino)tetralin 28-37 5-hydroxytryptamine receptor 1A Homo sapiens 4-19 1828519-1 1991 The 5-HT1A receptor agonists buspirone and 8-OH-DPAT have strong effects on serotoninergic systems. 8-Hydroxy-2-(di-n-propylamino)tetralin 43-52 5-hydroxytryptamine receptor 1A Homo sapiens 4-19 2052135-3 1991 In 1983 the very selective, high affinity 5-HT1A agonist 8-OH-DPAT was developed which allowed the pharmacology and distribution of the 5-HT1A receptor in the central nervous system of the rat and man to be extensively characterized. 8-Hydroxy-2-(di-n-propylamino)tetralin 57-66 5-hydroxytryptamine receptor 1A Homo sapiens 136-151 2178032-3 1990 The reductions of GABA-depolarizations which were produced by 1.0 microM 5-HT were mimicked by the 5-HT1A agonists 8-OH-DPAT (8-hydroxy-2-(n-dipropylamino)tetralin) and ipsapirone. 8-Hydroxy-2-(di-n-propylamino)tetralin 115-124 5-hydroxytryptamine receptor 1A Homo sapiens 99-105 2178032-6 1990 The presumptive 5-HT1A receptor-mediated effects of 1.0 microM 5-HT and 8-OH-DPAT appeared to result from a direct action on afferent terminals because the reduction of GABA responses was unchanged by addition of TTX to the Ringer"s solution. 8-Hydroxy-2-(di-n-propylamino)tetralin 72-81 5-hydroxytryptamine receptor 1A Homo sapiens 16-31 2078274-17 1990 Hyperpolarizing responses are also elicited by the 5-HT1A agonists, 8-hydroxy-di-n-propylaminotetralin (8-OH-DPAT) and 5-carboxyamidotryptamine. 8-Hydroxy-2-(di-n-propylamino)tetralin 104-113 5-hydroxytryptamine receptor 1A Homo sapiens 51-57 2117776-5 1990 The effects of serotonin on baseline and IL-2-activated NK cells were mimicked by the 5-HT1A receptor-specific agonists 8-OH-DPAT and (+)-ALK. 8-Hydroxy-2-(di-n-propylamino)tetralin 120-129 5-hydroxytryptamine receptor 1A Homo sapiens 86-101 2702482-9 1989 Regularly firing neurons were completely inhibited by low doses of the 5-HT1A agonist 8-hydroxy-dipropylamino-tetralin (8-OH-DPAT) (i.e. 2 micrograms/kg, i.v.) 8-Hydroxy-2-(di-n-propylamino)tetralin 120-129 5-hydroxytryptamine receptor 1A Homo sapiens 71-77 2140514-5 1990 Using acutely isolated, patch-clamped dorsal raphe neurons, we found that low concentrations of 5-HT and the 5-HT1A-selective agonist 8-OH-DPAT reversibly decrease whole-cell calcium current. 8-Hydroxy-2-(di-n-propylamino)tetralin 134-143 5-hydroxytryptamine receptor 1A Homo sapiens 109-115 2138222-4 1990 8-OH-DPAT (0.0625-4.0 micrograms) produced dose-dependent hypotension and bradycardia, which were antagonized by the 5-HT1A antagonists spiperone and spiroxatrine. 8-Hydroxy-2-(di-n-propylamino)tetralin 0-9 5-hydroxytryptamine receptor 1A Homo sapiens 117-123 1970424-6 1990 The increase in the behavioural deficit induced by 8-OH-DPAT, was likely to have resulted from stimulation of 5-HT1A receptors, since it was impaired by pretreatment with penbutolol, a beta-adrenergic-blocking drug, also known to bind to 5-HT1 receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 51-60 5-hydroxytryptamine receptor 1A Homo sapiens 110-116 1968842-0 1990 Response of cerebellar Purkinje cells to serotonin and the 5-HT1A agonists 8-OH-DPAT and ipsapirone in vitro. 8-Hydroxy-2-(di-n-propylamino)tetralin 75-84 5-hydroxytryptamine receptor 1A Homo sapiens 59-65 2575564-4 1989 The central 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produced hypotension and decreases in sympathetic nerve activity (SNA). 8-Hydroxy-2-(di-n-propylamino)tetralin 36-75 5-hydroxytryptamine receptor 1A Homo sapiens 12-27 2575564-4 1989 The central 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produced hypotension and decreases in sympathetic nerve activity (SNA). 8-Hydroxy-2-(di-n-propylamino)tetralin 77-86 5-hydroxytryptamine receptor 1A Homo sapiens 12-27 2732950-6 1989 The selective 5-HT1A agonist, 8-hydroxy-2(di-n-propylamino)tetralin, was the least potent but elicited a more intense vasoconstriction. 8-Hydroxy-2-(di-n-propylamino)tetralin 30-67 5-hydroxytryptamine receptor 1A Homo sapiens 14-20 2643854-2 1989 Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column. 8-Hydroxy-2-(di-n-propylamino)tetralin 58-97 5-hydroxytryptamine receptor 1A Homo sapiens 34-49 2643854-2 1989 Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column. 8-Hydroxy-2-(di-n-propylamino)tetralin 58-97 5-hydroxytryptamine receptor 1A Homo sapiens 34-40 2643854-2 1989 Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column. 8-Hydroxy-2-(di-n-propylamino)tetralin 99-108 5-hydroxytryptamine receptor 1A Homo sapiens 34-49 2643854-2 1989 Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column. 8-Hydroxy-2-(di-n-propylamino)tetralin 99-108 5-hydroxytryptamine receptor 1A Homo sapiens 34-40 1702490-3 1990 However, the central sympathoinhibition observed with 5-HT1A agonists such as 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is not uniform for all regional sympathetic outflows, renal outflow being the most sensitive. 8-Hydroxy-2-(di-n-propylamino)tetralin 78-87 5-hydroxytryptamine receptor 1A Homo sapiens 54-60 1702490-3 1990 However, the central sympathoinhibition observed with 5-HT1A agonists such as 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is not uniform for all regional sympathetic outflows, renal outflow being the most sensitive. 8-Hydroxy-2-(di-n-propylamino)tetralin 89-127 5-hydroxytryptamine receptor 1A Homo sapiens 54-60 25363799-2 2015 EXPERIMENTAL APPROACH: In vitro studies investigated the effect of THCV on targeting by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) of 5-HT1A receptors in membranes obtained from rat brainstem or human 5-HT1A CHO cells, using [(35)S]-GTPgammaS and 8-[(3)H]-OH-DPAT binding assays. 8-Hydroxy-2-(di-n-propylamino)tetralin 128-137 5-hydroxytryptamine receptor 1A Homo sapiens 209-215 2530993-1 1989 The influence of the centrally active 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on the exploration of objects was studied in hamsters, using a radioactographic method. 8-Hydroxy-2-(di-n-propylamino)tetralin 53-91 5-hydroxytryptamine receptor 1A Homo sapiens 38-44 2530993-1 1989 The influence of the centrally active 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on the exploration of objects was studied in hamsters, using a radioactographic method. 8-Hydroxy-2-(di-n-propylamino)tetralin 93-102 5-hydroxytryptamine receptor 1A Homo sapiens 38-44 2481192-10 1989 These results establish that the 5-HT1A receptor agonists flesinoxan and 8-OH-DPAT elicited a systemic and regional hemodynamic profile that differs from that of the alpha 2-adrenoceptor agonist clonidine. 8-Hydroxy-2-(di-n-propylamino)tetralin 73-82 5-hydroxytryptamine receptor 1A Homo sapiens 33-48 2533325-4 1989 In addition, 5-HT1A and 5-HT1C sites were directly visualized with the more selective radioligands [3H]8-OH-DPAT and [3H]mesulergine, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 103-112 5-hydroxytryptamine receptor 1A Homo sapiens 13-19 2529951-1 1989 Previous studies indicate that the selective 5-HT1A agonist, 8-OH DPAT, acts in the central nervous system to inhibit sympathetic nerve activity. 8-Hydroxy-2-(di-n-propylamino)tetralin 61-70 5-hydroxytryptamine receptor 1A Homo sapiens 45-51 2529951-12 1989 Rather, the data suggest that 8-OH DPAT acts postsynaptically on 5-HT1A receptors located on central sympathetic neurons to inhibit sympathetic nerve activity. 8-Hydroxy-2-(di-n-propylamino)tetralin 30-39 5-hydroxytryptamine receptor 1A Homo sapiens 65-71 2574684-2 1989 Indicative of anxiolytic effects the 5-HT1A agonists, buspirone, gepirone and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) all significantly increased social interaction time and open arm exploration time in the social interaction and elevated plus maze procedures, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 78-117 5-hydroxytryptamine receptor 1A Homo sapiens 37-43 2574684-2 1989 Indicative of anxiolytic effects the 5-HT1A agonists, buspirone, gepirone and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) all significantly increased social interaction time and open arm exploration time in the social interaction and elevated plus maze procedures, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 119-128 5-hydroxytryptamine receptor 1A Homo sapiens 37-43 2533356-1 1989 The repeated administration of 5-methoxy-N,N-dimethyltryptamine (5-MeODMT, 3 mg/kg, twice daily for 14 days) significantly diminished hypothermia and corticosterone secretion induced by an acute challenge with the 5-HT1A agonist 8-OH-DPAT (0.1 mg/kg) when compared to the responses in animals treated chronically with the solvent vehicle. 8-Hydroxy-2-(di-n-propylamino)tetralin 229-238 5-hydroxytryptamine receptor 1A Homo sapiens 214-220 2533356-5 1989 These data are consistent with other evidence that these physiological effects of 8-OH-DPAT and MK-212 are mediated by 5-HT1A and 5-HT2 receptors, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 82-91 5-hydroxytryptamine receptor 1A Homo sapiens 119-145 2887435-6 1987 The similar stimulus properties of 8-OHDPAT and the novel anxiolytics (buspirone, ipsapirone) are mirrored by the common abilities of these agents to selectively inhibit 5-HT1A binding and release punished responding. 8-Hydroxy-2-(di-n-propylamino)tetralin 35-43 5-hydroxytryptamine receptor 1A Homo sapiens 170-176 2976673-0 1988 NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 94-132 5-hydroxytryptamine receptor 1A Homo sapiens 79-85 2976673-0 1988 NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 134-143 5-hydroxytryptamine receptor 1A Homo sapiens 79-85 2905470-1 1988 Under several behavioral procedures, such as punished responding and drug discrimination, the effects of the atypical anxiolytic buspirone are similar to those of its analogue gepirone, and to those of the 5-HT1A receptor agonist 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 230-239 5-hydroxytryptamine receptor 1A Homo sapiens 206-221 2958301-4 1987 Two 5-HT1A ligands, LY165163 and 8-OH-DPAT, mimicked the effect of serotonin, although with slower kinetics. 8-Hydroxy-2-(di-n-propylamino)tetralin 33-42 5-hydroxytryptamine receptor 1A Homo sapiens 4-10 2471984-7 1989 Acute administration of the 5-HT1A receptor ligand 8-OH-DPAT (3.0 mg/kg) resulted in large decreases in 5-HIAA levels that persisted throughout the period of chronic administration. 8-Hydroxy-2-(di-n-propylamino)tetralin 51-60 5-hydroxytryptamine receptor 1A Homo sapiens 28-43 2521959-2 1989 5-HT1A and 5-HT1C binding sites were pharmacologically blocked using 100 nM 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) and 100 nM mesulergine, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 76-114 5-hydroxytryptamine receptor 1A Homo sapiens 0-6 2521959-2 1989 5-HT1A and 5-HT1C binding sites were pharmacologically blocked using 100 nM 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) and 100 nM mesulergine, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 116-125 5-hydroxytryptamine receptor 1A Homo sapiens 0-6 2535033-5 1989 5HT-1A receptor sites were detected by displacement experiments and by direct labeling with [3H]8-hydroxy-2(di-n-propylamino) tetralin 8OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 135-143 5-hydroxytryptamine receptor 1A Homo sapiens 0-15 2975354-6 1988 In contrast, these sites showed low affinity for drugs with high affinity and/or selectivity for 5-HT1A (8-OH-DPAT, buspirone), 5-HT1B (21-009, RU 24969), 5-HT1C (mesulergine, mianserin) and 5-HT2 sites (ketanserin, cinanserin). 8-Hydroxy-2-(di-n-propylamino)tetralin 105-114 5-hydroxytryptamine receptor 1A Homo sapiens 97-103 2969339-3 1988 spiperone, but not LY53837 (a 5-HT2 antagonist), antagonized the inhibition induced by 5-HT1A agonists 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) and buspirone in the dorsal raphe nucleus. 8-Hydroxy-2-(di-n-propylamino)tetralin 136-145 5-hydroxytryptamine receptor 1A Homo sapiens 87-93 2966310-1 1988 In human caudate and cortex membranes, [3H]serotonin ([3H]5-HT) labels 5-HT1A and 5-HT1C recognition sites which show nanomolar affinity for 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin) and mesulergine respectively, whereas no 5-HT1B binding could be identified. 8-Hydroxy-2-(di-n-propylamino)tetralin 141-150 5-hydroxytryptamine receptor 1A Homo sapiens 71-77 2966310-1 1988 In human caudate and cortex membranes, [3H]serotonin ([3H]5-HT) labels 5-HT1A and 5-HT1C recognition sites which show nanomolar affinity for 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin) and mesulergine respectively, whereas no 5-HT1B binding could be identified. 8-Hydroxy-2-(di-n-propylamino)tetralin 152-191 5-hydroxytryptamine receptor 1A Homo sapiens 71-77 2966310-5 1988 In contrast, these sites showed low affinity for drugs with high affinity and/or selectivity for 5-HT1A (8-OH-DPAT, buspirone), 5-HT1B (21-009, RU 24969), 5-HT1C (mesulergine, mianserin) and 5-HT2 sites (ketanserin, cinanserin). 8-Hydroxy-2-(di-n-propylamino)tetralin 105-114 5-hydroxytryptamine receptor 1A Homo sapiens 97-103 2901381-9 1988 The prototype 5HT1A agonist 8OH-DPAT may also have potential anxiolytic effects. 8-Hydroxy-2-(di-n-propylamino)tetralin 28-36 5-hydroxytryptamine receptor 1A Homo sapiens 14-19 2961966-0 1988 The 5-HT1A receptor probe [3H]8-OH-DPAT labels the 5-HT transporter in human platelets. 8-Hydroxy-2-(di-n-propylamino)tetralin 30-39 5-hydroxytryptamine receptor 1A Homo sapiens 4-19 2834759-3 1988 Antidepressant treatments also attenuate the temperature response to the 5-HT1A agonist 8-OH-DPAT but 5-HT2-receptor number and function are both decreased by antidepressant drugs but increased by ECS. 8-Hydroxy-2-(di-n-propylamino)tetralin 88-97 5-hydroxytryptamine receptor 1A Homo sapiens 73-79 3119155-3 1987 A hyperpolarization associated with an increased conductance state and insensitive to 5-HT2 antagonists was observed in 26% of the neurons and could be mimicked by the selective 5-HT1A agonist (+/-)-8-hydroxy-2-(di-N-propyl-amino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 194-238 5-hydroxytryptamine receptor 1A Homo sapiens 178-184 3119155-3 1987 A hyperpolarization associated with an increased conductance state and insensitive to 5-HT2 antagonists was observed in 26% of the neurons and could be mimicked by the selective 5-HT1A agonist (+/-)-8-hydroxy-2-(di-N-propyl-amino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 240-249 5-hydroxytryptamine receptor 1A Homo sapiens 178-184 2889156-6 1987 In contrast the hypothermic response which follows injection of the 5HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin-(8-OHDPAT) is attenuated not only after a range of diverse antidepressant drugs but also electroconvulsive shock. 8-Hydroxy-2-(di-n-propylamino)tetralin 91-130 5-hydroxytryptamine receptor 1A Homo sapiens 68-82 2889156-6 1987 In contrast the hypothermic response which follows injection of the 5HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin-(8-OHDPAT) is attenuated not only after a range of diverse antidepressant drugs but also electroconvulsive shock. 8-Hydroxy-2-(di-n-propylamino)tetralin 132-140 5-hydroxytryptamine receptor 1A Homo sapiens 68-82 3496228-6 1987 The corresponding values for the 5HT1A selective agonists 8-OH-DPAT and ipsapirone were 1.3 and 33 nmol/kg. 8-Hydroxy-2-(di-n-propylamino)tetralin 58-67 5-hydroxytryptamine receptor 1A Homo sapiens 33-38 3025366-3 1987 The 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin did not cause stimulation. 8-Hydroxy-2-(di-n-propylamino)tetralin 19-56 5-hydroxytryptamine receptor 1A Homo sapiens 4-10 32396921-5 2020 The results show that intra-mPFC infusion of the 5-HT1A receptor agonist 8-OH-DPAT induces rapid and long-lasting antidepressant-like effects in the forced swim, novelty-suppressed feeding, female urine sniffing, and chronic unpredictable stress tests. 8-Hydroxy-2-(di-n-propylamino)tetralin 73-82 5-hydroxytryptamine receptor 1A Homo sapiens 49-64 3013203-0 1986 Nucleotide interactions with 5-HT1A binding sites directly labeled by [3H]-8-hydroxy-2-(DI-n-propylamino)tetralin ([3H]-8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 115-129 5-hydroxytryptamine receptor 1A Homo sapiens 29-35 3013203-1 1986 Nucleotide interactions were examined at 5-hydroxytryptamine1A (5-HT1A) binding sites labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 142-151 5-hydroxytryptamine receptor 1A Homo sapiens 41-62 3013203-1 1986 Nucleotide interactions were examined at 5-hydroxytryptamine1A (5-HT1A) binding sites labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 142-151 5-hydroxytryptamine receptor 1A Homo sapiens 64-70 3720831-4 1986 The tetralin derivative 8-OH-DPAT, a drug with selective affinity for 5-HT1A binding sites, was a weak partial agonist on veins and completely devoid of any activity on the platelets. 8-Hydroxy-2-(di-n-propylamino)tetralin 24-33 5-hydroxytryptamine receptor 1A Homo sapiens 70-76 2942782-2 1986 5-HT and the preferential 5-HT1A receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] concentration-dependently inhibited the evoked 3H overflow. 8-Hydroxy-2-(di-n-propylamino)tetralin 50-59 5-hydroxytryptamine receptor 1A Homo sapiens 26-41 2942782-2 1986 5-HT and the preferential 5-HT1A receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] concentration-dependently inhibited the evoked 3H overflow. 8-Hydroxy-2-(di-n-propylamino)tetralin 61-99 5-hydroxytryptamine receptor 1A Homo sapiens 26-41 33384591-6 2020 The [3H]-8-OH-DPAT binding assay was used to determine the pharmacological interaction of CBD with 5-HT1A receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 9-18 5-hydroxytryptamine receptor 1A Homo sapiens 99-105 32315693-0 2020 Administration of low doses of the 5-HT1A receptor agonist 8-OH-DPAT attenuates the discriminative signal of amphetamine in the conditioned taste aversion procedure. 8-Hydroxy-2-(di-n-propylamino)tetralin 59-68 5-hydroxytryptamine receptor 1A Homo sapiens 35-50 32315693-4 2020 Additionally, to establish a correlation between the behavioral effects in drug discrimination and changes in dopamine (DA) and gamma-aminobutyric acid (GABA) concentrations, we evaluated the effect of systemic administration of low or high doses of the 5-HT1A receptor agonist 8-OH-DPAT and of the 5-HT1A receptor antagonist WAY100135 on DA and GABA extracellular concentrations in the nucleus accumbens (nAcc) and ventral tegmental area (VTA), respectively, using cerebral microdialysis. 8-Hydroxy-2-(di-n-propylamino)tetralin 278-287 5-hydroxytryptamine receptor 1A Homo sapiens 254-269 32315693-1 2020 Several studies have reported that low doses of the 5-HT1A receptor agonist 8-OH-DPAT reduce cocaine-induced locomotor activity. 8-Hydroxy-2-(di-n-propylamino)tetralin 76-85 5-hydroxytryptamine receptor 1A Homo sapiens 52-67 32315693-3 2020 This study aimed to evaluate the effects of low and high doses of the 5-HT1A agonist 8-OH-DPAT on the discriminative signal of AMPH using conditioned taste aversion as a drug discrimination procedure. 8-Hydroxy-2-(di-n-propylamino)tetralin 85-94 5-hydroxytryptamine receptor 1A Homo sapiens 70-76 31289857-4 2019 The 5-HT1A agonist 8-OH-DPAT (0.0125-0.1 mg/kg subcutaneous) increased impulsive action at low doses, but decreased it at higher doses, on the novel paced variable consecutive number with discriminative stimulus task (VCN). 8-Hydroxy-2-(di-n-propylamino)tetralin 19-28 5-hydroxytryptamine receptor 1A Homo sapiens 4-10 31289857-7 2019 We hypothesize that the biphasic effect of 8-OH-DPAT is due to actions on presynaptic raphe 5-HT1A autoreceptors, and also postsynaptic 5-HT1A receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 43-52 5-hydroxytryptamine receptor 1A Homo sapiens 92-98 31289857-7 2019 We hypothesize that the biphasic effect of 8-OH-DPAT is due to actions on presynaptic raphe 5-HT1A autoreceptors, and also postsynaptic 5-HT1A receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 43-52 5-hydroxytryptamine receptor 1A Homo sapiens 136-142 30347827-2 2018 Almost all of the studied compounds (except 5-HT1A receptor agonist (2R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT)) exhibited absolute cytotoxic activity against the examined cancer cells. 8-Hydroxy-2-(di-n-propylamino)tetralin 72-128 5-hydroxytryptamine receptor 1A Homo sapiens 44-59 30858018-6 2019 Likewise, intra-dlPAG injection of the 5-HT1A receptor agonist 8-OH-DPAT (3.2 nmol/0.2 u L) also reduced anxiety-like behavior, a response prevented by intra-dlPAG injection of AM251 (100 pmol/0.2 microL). 8-Hydroxy-2-(di-n-propylamino)tetralin 63-72 5-hydroxytryptamine receptor 1A Homo sapiens 39-54 30347827-2 2018 Almost all of the studied compounds (except 5-HT1A receptor agonist (2R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT)) exhibited absolute cytotoxic activity against the examined cancer cells. 8-Hydroxy-2-(di-n-propylamino)tetralin 130-139 5-hydroxytryptamine receptor 1A Homo sapiens 44-59 29660440-6 2018 5-HT1A receptor function, as measured by quantitative autoradiography of 8-OH-DPAT (1 muM)-stimulated [35S]GTPgammaS binding, was markedly reduced in hippocampus of weanling female, but not male offspring (postnatal day, PND 21) of dams fed the low protein diet. 8-Hydroxy-2-(di-n-propylamino)tetralin 73-82 5-hydroxytryptamine receptor 1A Homo sapiens 0-15 29057454-2 2018 EXPERIMENTAL APPROACH: We investigated the effects of HU-580 and CBDA on (i) activation by 8-hydroxy-2-(di-n-propylamino)tetralin of human 5-HT1A receptors in CHO cell membranes, using [35 S]-GTPgammaS binding assays, (ii) gaping by rats in acute and anticipatory nausea models, and (iii) stress-induced anxiety-like behaviour, as indicated by exit time from the light compartment of a light-dark box of rats subjected 24 h earlier to six tone-paired foot shocks. 8-Hydroxy-2-(di-n-propylamino)tetralin 91-129 5-hydroxytryptamine receptor 1A Homo sapiens 139-145 29730825-13 2018 Although 18F-F13640 in vivo binding was blocked by the 5-HT1A antagonist WAY-100635 and the 5-HT1A agonist 8-OH-DPAT, the distribution pattern was markedly different from antagonist radiotracers in the three species, suggesting it provides novel information on 5-HT1A receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 107-116 5-hydroxytryptamine receptor 1A Homo sapiens 92-98 29730825-13 2018 Although 18F-F13640 in vivo binding was blocked by the 5-HT1A antagonist WAY-100635 and the 5-HT1A agonist 8-OH-DPAT, the distribution pattern was markedly different from antagonist radiotracers in the three species, suggesting it provides novel information on 5-HT1A receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 107-116 5-hydroxytryptamine receptor 1A Homo sapiens 92-98 29339052-2 2018 To provide more detailed information on the processes underlying the alleviation of dyskinesia, we have here investigated changes in the spectral contents of local field potentials in cortico-basal ganglia-thalamic circuits following treatment with this novel group of 5-HT1A agonists or the prototypical agonist, 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 314-323 5-hydroxytryptamine receptor 1A Homo sapiens 269-275 26856853-7 2016 Dose-effect curves for the 5-HT1A-mediated hyperactivity produced by the 5-HT1A agonist, 8-OH-DPAT, and the 5-HT1B-mediated adipsic response produced by RU 24969 were shifted rightward, suggesting a desensitization of 5-HT1A and 5-HT1B receptor mechanisms. 8-Hydroxy-2-(di-n-propylamino)tetralin 89-98 5-hydroxytryptamine receptor 1A Homo sapiens 27-33 28347824-10 2017 Association of ineffective doses of Nor-BNI and the 5-HT1A-R agonist 8-OH-DPAT caused panicolytic-like effect in these two tests. 8-Hydroxy-2-(di-n-propylamino)tetralin 69-78 5-hydroxytryptamine receptor 1A Homo sapiens 52-58 26612522-4 2016 An approach that has undergone considerable empirical research after TBI is pharmacological targeting of 5-HT1A receptors with agonists such as repinotan HCl, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), and buspirone. 8-Hydroxy-2-(di-n-propylamino)tetralin 159-198 5-hydroxytryptamine receptor 1A Homo sapiens 105-111 26612522-4 2016 An approach that has undergone considerable empirical research after TBI is pharmacological targeting of 5-HT1A receptors with agonists such as repinotan HCl, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), and buspirone. 8-Hydroxy-2-(di-n-propylamino)tetralin 200-209 5-hydroxytryptamine receptor 1A Homo sapiens 105-111 26876117-6 2016 Interestingly, co-incubation of heterodimer-expressing HEK 293 cells with clozapine and the 5-HT1 A R agonist 8-OH DPAT potentiated post-synaptic effects, especially with respect to ERK activation. 8-Hydroxy-2-(di-n-propylamino)tetralin 110-119 5-hydroxytryptamine receptor 1A Homo sapiens 92-99 26749090-7 2016 DMH treatment with 8-OH-DPAT decreased escape responses, which strongly suggests that the 5-HT1A receptor modulates the defensive responses. 8-Hydroxy-2-(di-n-propylamino)tetralin 19-28 5-hydroxytryptamine receptor 1A Homo sapiens 90-105 25687330-4 2015 Unexpectedly, 5-hydroxytryptamine 1A receptor (5-HT1A) agonist 8-OH-DPAT did not decrease forskolin-induced tau hyperphosphorylation. 8-Hydroxy-2-(di-n-propylamino)tetralin 63-72 5-hydroxytryptamine receptor 1A Homo sapiens 47-53 25304920-5 2014 The purpose of the present study is to determine 5-HT1A receptor-induced G-protein functional activation by 8-OH-DPAT-stimulated [(35)S]GTPgammaS binding assay in hippocampal tissue of surgical patients with mTLE. 8-Hydroxy-2-(di-n-propylamino)tetralin 108-117 5-hydroxytryptamine receptor 1A Homo sapiens 49-64 25288485-3 2015 Using a pharmacological approach, we found that the 5-HT1A agonist 8-OH-DPAT also potentiated the antidepressant-like effects of cytisine, suggesting that this subtype might mediate the interaction between the serotonergic and cholinergic systems. 8-Hydroxy-2-(di-n-propylamino)tetralin 67-76 5-hydroxytryptamine receptor 1A Homo sapiens 52-58 26080602-1 2015 We have found that activation of 5-HT1A receptor with 8-OH-DPAT (0.1, 0.5 and 1.0 mg/kg, i. p.) considerably and dose-dependently reduced the number of 5-HT2A receptor-mediated head-twitches, whereas 5-HT1A receptor blockade with WAY-100635 (0.5 and 1.0 mg/kg, i. p.), on the contrary, pro- duced significant enhancement of this 5-HT2A receptor functional response. 8-Hydroxy-2-(di-n-propylamino)tetralin 54-63 5-hydroxytryptamine receptor 1A Homo sapiens 33-48 26080602-1 2015 We have found that activation of 5-HT1A receptor with 8-OH-DPAT (0.1, 0.5 and 1.0 mg/kg, i. p.) considerably and dose-dependently reduced the number of 5-HT2A receptor-mediated head-twitches, whereas 5-HT1A receptor blockade with WAY-100635 (0.5 and 1.0 mg/kg, i. p.), on the contrary, pro- duced significant enhancement of this 5-HT2A receptor functional response. 8-Hydroxy-2-(di-n-propylamino)tetralin 54-63 5-hydroxytryptamine receptor 1A Homo sapiens 200-215 24429224-5 2014 The results showed that both clozapine and norclozapine, although with a 20-fold lower affinity, displaced [3H]8-OH-DPAT binding in all of the brain regions analysed, suggesting their interaction with 5-HT(1A) receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 111-120 5-hydroxytryptamine receptor 1A Homo sapiens 201-208 24830553-7 2014 Previously, it was shown that Ktl is in a complex with the Drosophila 5-HT receptor 5-HT7, and we observed that both Ktl and the 5-HT1A receptor are required in insulin-producing cells (IPCs) for proper adult male behaviour, as well as for hyperaggressive activity induced by the mammalian 5-HT1A receptor agonist 8-hydroxy-2-dipropylaminotetralin-hydrobromide. 8-Hydroxy-2-(di-n-propylamino)tetralin 314-360 5-hydroxytryptamine receptor 1A Homo sapiens 129-144 24385311-8 2014 Instead, CUMI-101 behaved as a potent 5-HT1A receptor antagonist by dose-dependently inhibiting 8-OH-DPAT-stimulated (35)S-GTPgammaS binding. 8-Hydroxy-2-(di-n-propylamino)tetralin 96-105 5-hydroxytryptamine receptor 1A Homo sapiens 38-53 24157794-4 2013 The findings show that coagonist treatment with 8-OH-DPAT and FGF2 but not treatment with the 5-HT1A agonist alone markedly increases the BRETmax values and significantly reduces the BRET50 values of 5HT1A homodimerization. 8-Hydroxy-2-(di-n-propylamino)tetralin 48-57 5-hydroxytryptamine receptor 1A Homo sapiens 200-205 24157794-8 2013 Furthermore, FGF2 alone produced a small increase in the BRET(2) signal from the 5-HT1A-beta-arrestin2 receptor-protein complex which was additive to the marked effect of 8-OH-DPAT alone. 8-Hydroxy-2-(di-n-propylamino)tetralin 171-180 5-hydroxytryptamine receptor 1A Homo sapiens 81-87 23299041-7 2013 5-HT1A receptor agonist 8-OH-DPAT (0.2 and 0.5mg/kg) decreased aggressive behavior in both A infant and adult rats. 8-Hydroxy-2-(di-n-propylamino)tetralin 24-33 5-hydroxytryptamine receptor 1A Homo sapiens 0-15 23354536-4 2013 The response to the 5-HT1a agonist, 8-OHDPAT (0.003-0.5 mg/kg, SC), was assessed using lower lip retraction (LLR), hypoactivity, and 5-hydroxytryptophan (5-HTP) accumulation following decarboxylase inhibition. 8-Hydroxy-2-(di-n-propylamino)tetralin 36-44 5-hydroxytryptamine receptor 1A Homo sapiens 20-26 22735975-5 2012 Food intake was measured in chickens after centrally administered lipopolysaccharide (LPS) (20 ng) (0 h), followed by intracerebroventricular (ICV) injection of the 5-HT(1A) autoreceptor agonist (8-OH-DPAT, 61 nmol), 5-HT(2c) receptor antagonist (SB 242084, 30 nm), and NMDA receptor antagonist (DL-AP5, 5 nm) at the onset of anorexia (4 h). 8-Hydroxy-2-(di-n-propylamino)tetralin 196-205 5-hydroxytryptamine receptor 1A Homo sapiens 165-172 22940695-6 2012 As measured by autoradiography with [(3)H]8-hydroxy-2-(di-n-propyl) aminotetralin (8-OH-DPAT), a decrease of 5-HT(1A) receptor specific binding was observed in the posterior/dorsal region of the anterior cingulate gyrus and posterior/ventral area of the superior frontal gyrus of MPTP monkeys compared to controls. 8-Hydroxy-2-(di-n-propylamino)tetralin 83-92 5-hydroxytryptamine receptor 1A Homo sapiens 109-126 20709144-4 2010 A concentration-related inhibition of withdrawal was observed when methamphetamine-exposed planarians were placed into a solution containing either methamphetamine and 5-HT (0.1-100 muM) or methamphetamine and the 5-HT(1A) receptor agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) (10, 20 muM). 8-Hydroxy-2-(di-n-propylamino)tetralin 240-278 5-hydroxytryptamine receptor 1A Homo sapiens 214-231 20656461-4 2011 We show that administration of the 5-HT(1A) receptor agonist 8-OH-DPAT prompts a dose-dependent reduction in local cerebral blood volume (CBV) in brain areas rich in neurons expressing post-synaptic 5-HT(1A) receptor, including the prefrontal cortex, hippocampus and amygdalar nuclei. 8-Hydroxy-2-(di-n-propylamino)tetralin 61-70 5-hydroxytryptamine receptor 1A Homo sapiens 199-216 22465320-0 2012 Elucidating the role of 5-HT(1A) and 5-HT(7) receptors on 8-OH-DPAT-induced behavioral recovery after experimental traumatic brain injury. 8-Hydroxy-2-(di-n-propylamino)tetralin 58-67 5-hydroxytryptamine receptor 1A Homo sapiens 24-31 22465320-1 2012 8-OH-DPAT is a 5-HT(1A/7) receptor agonist that enhances behavioral recovery after traumatic brain injury (TBI). 8-Hydroxy-2-(di-n-propylamino)tetralin 0-9 5-hydroxytryptamine receptor 1A Homo sapiens 15-22 22465320-2 2012 This study is a first attempt to decipher whether the benefits induced by 8-OH-DPAT after TBI are mediated by 5-HT(1A) or 5-HT(7) receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 74-83 5-hydroxytryptamine receptor 1A Homo sapiens 110-117 22465320-9 2012 Evaluation of a specific 5-HT(7) receptor agonist will further elucidate the contribution of 5-HT(1A) and 5-HT(7) receptors on behavioral recovery conferred by acute 8-OH-DPAT treatment after TBI. 8-Hydroxy-2-(di-n-propylamino)tetralin 166-175 5-hydroxytryptamine receptor 1A Homo sapiens 93-100 21899601-2 2011 Application of the 5-HT(1A) receptor (5-HT(1A) R) agonist 8-OH-DPAT was shown (i) to depress cellular cAMP, leading to dephosphorylation of Glyalpha(3) R and augmentation of postsynaptic inhibition of neurons expressing Glyalpha(3) R (Manzke et al., 2010) and (ii) to hyperpolarize respiratory neurons through 5-HT-activated potassium channels. 8-Hydroxy-2-(di-n-propylamino)tetralin 59-68 5-hydroxytryptamine receptor 1A Homo sapiens 19-26 21899601-2 2011 Application of the 5-HT(1A) receptor (5-HT(1A) R) agonist 8-OH-DPAT was shown (i) to depress cellular cAMP, leading to dephosphorylation of Glyalpha(3) R and augmentation of postsynaptic inhibition of neurons expressing Glyalpha(3) R (Manzke et al., 2010) and (ii) to hyperpolarize respiratory neurons through 5-HT-activated potassium channels. 8-Hydroxy-2-(di-n-propylamino)tetralin 59-68 5-hydroxytryptamine receptor 1A Homo sapiens 39-46 20520769-9 2010 Concordantly, the administration of 5-HT, 8-OH-DPAT (a specific 5-HT1A receptor agonist), or fluoxetine (a 5-HT reuptake inhibitor) increased tubulin acetylation. 8-Hydroxy-2-(di-n-propylamino)tetralin 42-51 5-hydroxytryptamine receptor 1A Homo sapiens 64-79 20802053-2 2010 Opioid-induced ventilatory depression was shown to be counteracted in anesthetized rats by serotonin(1A)-receptor (5-HT(1A)-R)-agonist 8-OH-DPAT, which cannot be applied to humans. 8-Hydroxy-2-(di-n-propylamino)tetralin 135-144 5-hydroxytryptamine receptor 1A Homo sapiens 115-122 20450907-0 2010 Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 52-61 5-hydroxytryptamine receptor 1A Homo sapiens 28-43 20450907-0 2010 Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 96-105 5-hydroxytryptamine receptor 1A Homo sapiens 28-43 20450907-0 2010 Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 96-105 5-hydroxytryptamine receptor 1A Homo sapiens 28-43 20450907-1 2010 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is the prototypical agonist at serotonin 5-HT1A receptors; however, activity at other targets contributes to the functional effects of the compound as well. 8-Hydroxy-2-(di-n-propylamino)tetralin 0-9 5-hydroxytryptamine receptor 1A Homo sapiens 92-98 20450907-1 2010 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is the prototypical agonist at serotonin 5-HT1A receptors; however, activity at other targets contributes to the functional effects of the compound as well. 8-Hydroxy-2-(di-n-propylamino)tetralin 11-49 5-hydroxytryptamine receptor 1A Homo sapiens 92-98 20223238-7 2010 In the second experiment, the effects of prior treatment with fluoxetine on the lordosis inhibitory effect of the 5-HT(1A) receptor agonist, (+/-)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), were studied. 8-Hydroxy-2-(di-n-propylamino)tetralin 141-182 5-hydroxytryptamine receptor 1A Homo sapiens 114-131 20223238-7 2010 In the second experiment, the effects of prior treatment with fluoxetine on the lordosis inhibitory effect of the 5-HT(1A) receptor agonist, (+/-)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), were studied. 8-Hydroxy-2-(di-n-propylamino)tetralin 184-193 5-hydroxytryptamine receptor 1A Homo sapiens 114-131 20488186-6 2010 Xenopus oocytes injected with toadfish 5-HT(1A) receptor cRNA displayed significantly higher binding of [(3)H]5-HT that was abolished by the mammalian 5-HT(1A) receptor agonist, 8-OH-DPAT, indicating a conserved binding site of the toadfish 5-HT(1A) receptor and a high specificity for the agonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 178-187 5-hydroxytryptamine receptor 1A Homo sapiens 39-56 20488186-6 2010 Xenopus oocytes injected with toadfish 5-HT(1A) receptor cRNA displayed significantly higher binding of [(3)H]5-HT that was abolished by the mammalian 5-HT(1A) receptor agonist, 8-OH-DPAT, indicating a conserved binding site of the toadfish 5-HT(1A) receptor and a high specificity for the agonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 178-187 5-hydroxytryptamine receptor 1A Homo sapiens 151-168 20488186-6 2010 Xenopus oocytes injected with toadfish 5-HT(1A) receptor cRNA displayed significantly higher binding of [(3)H]5-HT that was abolished by the mammalian 5-HT(1A) receptor agonist, 8-OH-DPAT, indicating a conserved binding site of the toadfish 5-HT(1A) receptor and a high specificity for the agonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 178-187 5-hydroxytryptamine receptor 1A Homo sapiens 151-168 18667366-5 2008 In this study we showed that intracisternal injection of a low dose (1 microg/kg) of the 5-HT(1A) receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), significantly reduced the increases in heart rate and renal sympathetic nerve activity evoked by disinhibition of the DMH, but had no effect on these responses when injected intravenously. 8-Hydroxy-2-(di-n-propylamino)tetralin 156-165 5-hydroxytryptamine receptor 1A Homo sapiens 89-106 19447286-3 2009 At 24-48 h acutely 8-OH-DPAT (0.062 mg/kg) administration enhanced memory and attenuated mRNA 5-HT(1A)<5-HT(7) receptors expression respect to saline group. 8-Hydroxy-2-(di-n-propylamino)tetralin 19-28 5-hydroxytryptamine receptor 1A Homo sapiens 94-101 19447286-7 2009 Together these data revealed that, when both 5-HT(1A) and 5-HT(7) receptors were stimulated by 8-OHDPAT under memory consolidation, subtle changes emerged, not evident at behavioral level though detectable at genes expression. 8-Hydroxy-2-(di-n-propylamino)tetralin 95-103 5-hydroxytryptamine receptor 1A Homo sapiens 45-52 19075042-3 2009 The 5-HT(1A) receptor agonist, 8-hydroxy-2-dipropylaminotetralin, produced an increase in contractions that was highly variable, of low potency, and was not significantly inhibited by the 5-HT(1A) antagonist WAY100635 [[O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide]. 8-Hydroxy-2-(di-n-propylamino)tetralin 31-64 5-hydroxytryptamine receptor 1A Homo sapiens 4-21 19913081-8 2010 Only Uncaria hook (3.13-50 microg/ml), of the seven constituent herbal extracts, inhibited the [(3)H]8-OH-DPAT binding to 5-HT1A receptors in a concentration-dependent manner, and the IC(50) value was estimated to be 7.42 microg/ml. 8-Hydroxy-2-(di-n-propylamino)tetralin 101-110 5-hydroxytryptamine receptor 1A Homo sapiens 122-128 18667366-5 2008 In this study we showed that intracisternal injection of a low dose (1 microg/kg) of the 5-HT(1A) receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), significantly reduced the increases in heart rate and renal sympathetic nerve activity evoked by disinhibition of the DMH, but had no effect on these responses when injected intravenously. 8-Hydroxy-2-(di-n-propylamino)tetralin 116-154 5-hydroxytryptamine receptor 1A Homo sapiens 89-106 18667366-6 2008 Subsequent intracisternal administration of the 5-HT(1A) receptor antagonist WAY-100635 restored the DMH-evoked cardiovascular responses to levels observed before 8-OH-DPAT administration. 8-Hydroxy-2-(di-n-propylamino)tetralin 163-172 5-hydroxytryptamine receptor 1A Homo sapiens 48-65 18469535-6 2008 The decrease in pLMV induced by the5-HT1A agonist (8-OH-DPAT), and the 5-HT1B/2C agonist (mCPP), was antagonized by pretreatment with the 5-HT1A antagonist (WAY-100635) at a dose that had no effect of its own on pLMV. 8-Hydroxy-2-(di-n-propylamino)tetralin 51-60 5-hydroxytryptamine receptor 1A Homo sapiens 35-41 18513131-3 2008 In preclinical studies, it has been demonstrated that R (+)-8-hydroxy-dipropylaminotetralin (8-OHDPAT), a 5-HT1A agonist, has anxiolytic properties. 8-Hydroxy-2-(di-n-propylamino)tetralin 93-101 5-hydroxytryptamine receptor 1A Homo sapiens 106-112 18622186-0 2008 Behavior selectively elicited by novel stimuli: modulation by the 5-HT1A agonist 8-OHDPAT and antagonist WAY-100635. 8-Hydroxy-2-(di-n-propylamino)tetralin 81-89 5-hydroxytryptamine receptor 1A Homo sapiens 66-72 18455431-3 2008 In the presence of NMDA, a low concentration of the 5-HT(1A) agonist 8-OH-DPAT substantially reduced the number of spikes, and a low concentration of the 5-HT(2A/C) agonist alpha-Me-5HT significantly enhanced it, while both agonists were ineffective when applied alone. 8-Hydroxy-2-(di-n-propylamino)tetralin 69-78 5-hydroxytryptamine receptor 1A Homo sapiens 52-59 18410179-3 2008 Subcutaneous injections of the selective 5-HT(1A) agonist 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT), a drug that reduces 5-HT release by acting on presynaptic autoreceptors, dose-dependently increased consumption of 0.45 M NaCl in a one-bottle test. 8-Hydroxy-2-(di-n-propylamino)tetralin 58-95 5-hydroxytryptamine receptor 1A Homo sapiens 41-48 18410179-3 2008 Subcutaneous injections of the selective 5-HT(1A) agonist 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT), a drug that reduces 5-HT release by acting on presynaptic autoreceptors, dose-dependently increased consumption of 0.45 M NaCl in a one-bottle test. 8-Hydroxy-2-(di-n-propylamino)tetralin 97-106 5-hydroxytryptamine receptor 1A Homo sapiens 41-48 18289523-1 2008 The effect of chronic citalopram or escitalopram administration on 5-HT1A receptor function in the dorsal raphe nucleus was determined by measuring [35S]GTP gamma S binding stimulated by the 5-HT1A receptor agonist (R)-(+)-8-OH-DPAT (1nM-10 microM). 8-Hydroxy-2-(di-n-propylamino)tetralin 215-232 5-hydroxytryptamine receptor 1A Homo sapiens 67-82 18289523-1 2008 The effect of chronic citalopram or escitalopram administration on 5-HT1A receptor function in the dorsal raphe nucleus was determined by measuring [35S]GTP gamma S binding stimulated by the 5-HT1A receptor agonist (R)-(+)-8-OH-DPAT (1nM-10 microM). 8-Hydroxy-2-(di-n-propylamino)tetralin 215-232 5-hydroxytryptamine receptor 1A Homo sapiens 191-206 18094064-3 2008 We previously showed in conscious piglets that activation of 5-HT1A receptors with (+/-)-8-hydroxy-2-(dipropylamino)-tetralin (8-OH-DPAT) in the paragigantocellularis lateralis (PGCL), a medullary region lateral to the raphe that contains substantial numbers of 5-HT neurons, eliminates rapid eye movement (REM) sleep and decreases shivering in a cold environment, but does not attenuate peripheral vasoconstriction. 8-Hydroxy-2-(di-n-propylamino)tetralin 83-125 5-hydroxytryptamine receptor 1A Homo sapiens 61-67 18269931-6 2008 The results indicate that both NR1 subunit phosphorylation and the neurotrophin BDNF account, at least in part, for the neuroprotective effect of 8-OH-DPAT on cell damage induced by global ischemia in the gerbil hippocampus and support the potential interest of 5-HT1A receptor activation in the search for neuroprotective strategies. 8-Hydroxy-2-(di-n-propylamino)tetralin 146-155 5-hydroxytryptamine receptor 1A Homo sapiens 262-277 18094064-3 2008 We previously showed in conscious piglets that activation of 5-HT1A receptors with (+/-)-8-hydroxy-2-(dipropylamino)-tetralin (8-OH-DPAT) in the paragigantocellularis lateralis (PGCL), a medullary region lateral to the raphe that contains substantial numbers of 5-HT neurons, eliminates rapid eye movement (REM) sleep and decreases shivering in a cold environment, but does not attenuate peripheral vasoconstriction. 8-Hydroxy-2-(di-n-propylamino)tetralin 127-136 5-hydroxytryptamine receptor 1A Homo sapiens 61-67 18094064-9 2008 The effects of 8-OH-DPAT were prevented after dialysis of the selective 5-HT1A receptor antagonist WAY-100635. 8-Hydroxy-2-(di-n-propylamino)tetralin 15-24 5-hydroxytryptamine receptor 1A Homo sapiens 72-87 17663006-7 2007 NHE activity was significantly increased by 8-OH-DPAT and alpha-methyl-5-HT, agonists of, respectively, 5-HT(1A) and 5-HT(2) receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 44-53 5-hydroxytryptamine receptor 1A Homo sapiens 104-111 17675218-7 2008 The patients with cardiovascular disease showed a reduction (-50.40%) (p<0.01) of the 3H-8OH-DPAT bound to the platelet membranes 5-HT1A receptors (1.652+/-0.79 fmol/mg protein) with respect to the control group (3.331+/-0.16 fmol/mg protein). 8-Hydroxy-2-(di-n-propylamino)tetralin 92-100 5-hydroxytryptamine receptor 1A Homo sapiens 133-139 17916336-4 2007 In the current study, the effects of iontophoretic application of the 5-HT 1A agonist 8-OH-DPAT on auditory responses were compared with the characteristic frequencies (CFs), recording depths, and control first-spike latencies of the same group of IC neurons. 8-Hydroxy-2-(di-n-propylamino)tetralin 86-95 5-hydroxytryptamine receptor 1A Homo sapiens 70-77 17392335-2 2007 Activation of presynaptic 5-HT(1A) receptors inhibits serotonergic neurones in the ventral medulla and caudal raphe, and we tested the hypothesis that administration of 8-hydroxydipropylaminotetralin (8-OH-DPAT), a 5-HT(1A) agonist, within the rostroventral medulla and caudal raphe would enhance baroreceptor-mediated inhibition of respiratory activity in decerebrate, neonatal piglets. 8-Hydroxy-2-(di-n-propylamino)tetralin 201-210 5-hydroxytryptamine receptor 1A Homo sapiens 26-33 17392335-9 2007 We conclude that activation of 5-HT(1A) receptors after systemic administration of 8-OH-DPAT enhanced baroreflex-mediated inhibition of ventilation, but this effect cannot be attributed to 5-HT(1A) receptor activation within the rostroventral medulla and caudal raphe. 8-Hydroxy-2-(di-n-propylamino)tetralin 83-92 5-hydroxytryptamine receptor 1A Homo sapiens 31-38 17392335-9 2007 We conclude that activation of 5-HT(1A) receptors after systemic administration of 8-OH-DPAT enhanced baroreflex-mediated inhibition of ventilation, but this effect cannot be attributed to 5-HT(1A) receptor activation within the rostroventral medulla and caudal raphe. 8-Hydroxy-2-(di-n-propylamino)tetralin 83-92 5-hydroxytryptamine receptor 1A Homo sapiens 31-48 16839691-2 2006 Therefore, the aim of the present study was to examine the role of endogenous and exogenous ovarian steroids in the induction of perseverative responses in a T-maze by the 5-HT1A agonist 8-OH-DPAT (1.0 and 2.0 mg/kg, SC) and in the preventive action of the selective serotonin reuptake inhibitor, fluoxetine (10.0 mg/kg, three times, SC). 8-Hydroxy-2-(di-n-propylamino)tetralin 187-196 5-hydroxytryptamine receptor 1A Homo sapiens 172-178 17431134-5 2007 The preadministration of the 5-HT(1A) receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT) (1 and 40 microg/kg) significantly enhanced the venlafaxine inhibitory effect, decreasing the ED(50) by 56 and 44%, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 55-88 5-hydroxytryptamine receptor 1A Homo sapiens 29-46 17431134-5 2007 The preadministration of the 5-HT(1A) receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT) (1 and 40 microg/kg) significantly enhanced the venlafaxine inhibitory effect, decreasing the ED(50) by 56 and 44%, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 90-99 5-hydroxytryptamine receptor 1A Homo sapiens 29-46 17416565-6 2007 The present study shows that responses to 8-hydroxy-2-(di-n-propylamino)tetraline (8-OH-DPAT), a selective 5-HT 1A agonist decreased following exposure to single stress and the decreases were normalized following adaptation to stress. 8-Hydroxy-2-(di-n-propylamino)tetralin 83-92 5-hydroxytryptamine receptor 1A Homo sapiens 107-114 17141811-6 2007 Adaptive changes in 5-HT(1A) receptor function were studied by measuring 8-OH-DPAT-mediated hypothermia and lower lip retraction (LLR) in the animals 24h after LH test session. 8-Hydroxy-2-(di-n-propylamino)tetralin 73-82 5-hydroxytryptamine receptor 1A Homo sapiens 20-37 20641465-11 2004 Selective agonists such as 8-hydroxy-N-N-dipropylaminotetralin (8-OH-DPAT) were initially studied, but because they bind to the relatively few 5-HT1A receptors in the high-affinity state, the higher affinity required in that situation was difficult to achieve (6). 8-Hydroxy-2-(di-n-propylamino)tetralin 64-73 5-hydroxytryptamine receptor 1A Homo sapiens 143-149 17493597-5 2007 (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (a 5-HT1A receptor agonist, 1 and 2 mg/kg) markedly reduced paired-pulse inhibition in the CA1 region of SS adult gerbils only. 8-Hydroxy-2-(di-n-propylamino)tetralin 0-44 5-hydroxytryptamine receptor 1A Homo sapiens 48-63 17321680-1 2007 The 5-HT(1A) receptor agonist 8-OH-DPAT (0.5mg/kg) enhances behavioral recovery when administered 15min after experimental traumatic brain injury (TBI). 8-Hydroxy-2-(di-n-propylamino)tetralin 30-39 5-hydroxytryptamine receptor 1A Homo sapiens 4-21 16452654-7 2006 Paradoxically, systemic administration of the 5-HT1a agonist 8-OH-DPAT also attenuated LTP. 8-Hydroxy-2-(di-n-propylamino)tetralin 61-70 5-hydroxytryptamine receptor 1A Homo sapiens 46-52 16730359-6 2006 The inhibition of the synthesis of 5-HT by p-chlorophenylalanine and the pre-administration of the 5-HT(1A) receptor agonist, 8-OH-DPAT at 40microg/kg, caused a significant potentiation of the tramadol effect decreasing the ED(50) by 53% and 67% respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 126-135 5-hydroxytryptamine receptor 1A Homo sapiens 99-116 16447179-4 2006 The purpose of this work is to determine the specific binding sites using [(3)H]8-hydroxy-2(di-n-propylamino)tetralin ([(3)H]8-OH-DPAT), a specific agonist of the 5-HT(1A) receptor, and to characterize the diurnal rhythm in the binding by an autoradiography procedure in the crayfish ES. 8-Hydroxy-2-(di-n-propylamino)tetralin 124-134 5-hydroxytryptamine receptor 1A Homo sapiens 163-180 16148240-5 2005 We analyzed sleep before and after unilaterally dialyzing the 5-HT1A agonist (+/-)-8-hydroxy-2-(dipropylamino)-tetralin (8-OH-DPAT) into the juxtafacial PGCL in conscious newborn piglets. 8-Hydroxy-2-(di-n-propylamino)tetralin 121-130 5-hydroxytryptamine receptor 1A Homo sapiens 62-68 16081165-4 2005 Apoptotic and non-apoptotic fetal rhombencephalic neurons were quantitated in primary cultures that were treated with 50 mM ethanol and with 100 nM of a 5-HT1A agonist such as 8-OH-DPAT [8-hydroxy 2-(di-n-propylamino)tetralin], ipsapirone, or buspirone. 8-Hydroxy-2-(di-n-propylamino)tetralin 176-185 5-hydroxytryptamine receptor 1A Homo sapiens 153-159 16148240-8 2005 The effects of 8-OH-DPAT were blocked by local pretreatment with N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexane-carboxamide, a selective 5-HT1A antagonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 15-24 5-hydroxytryptamine receptor 1A Homo sapiens 162-168 15829255-2 2005 Pre-training administration of the 5-HT1A receptor agonist 8-OH-DPAT impaired WM performance and facilitated PA retention at low doses (0.01 and 0.03 mg/kg) and impaired PA retention at higher doses (0.1-1.0 mg/kg). 8-Hydroxy-2-(di-n-propylamino)tetralin 59-68 5-hydroxytryptamine receptor 1A Homo sapiens 35-50 15234111-4 2004 Moreover, the 5-HT(1A) receptor agonist 8-OH-DPAT (1 microM) mimicked the 5-HT effect. 8-Hydroxy-2-(di-n-propylamino)tetralin 40-49 5-hydroxytryptamine receptor 1A Homo sapiens 14-31 15364487-4 2004 or s.c.) after training, significantly decreased the improvement of performance produced by the 5-HT(1A/7) agonist 8-OH-DPAT to levels lower than controls". 8-Hydroxy-2-(di-n-propylamino)tetralin 115-124 5-hydroxytryptamine receptor 1A Homo sapiens 96-103 15469667-5 2004 5-HT1A receptor binding was assayed in post-mortem prefrontal cortex using [3H]8-OH-DPAT, and specific binding determined by 1 microM 5-HT. 8-Hydroxy-2-(di-n-propylamino)tetralin 79-88 5-hydroxytryptamine receptor 1A Homo sapiens 0-15 15721170-4 2005 The 5-HT(1A) agonists 8-OH-DPAT and buspirone mimic the effect of 5-HT, whereas the selective 5-HT(1A) receptor antagonist WAY-100635 (1 microM) significantly prevents the effect of 5-HT. 8-Hydroxy-2-(di-n-propylamino)tetralin 22-31 5-hydroxytryptamine receptor 1A Homo sapiens 4-11 15722055-6 2005 Pretreatment with local injections of p-MPPI (an antagonist of 5-HT1A receptors) attenuated the ingestive responses evoked by 8-OH-DPAT injections. 8-Hydroxy-2-(di-n-propylamino)tetralin 126-135 5-hydroxytryptamine receptor 1A Homo sapiens 63-69 15482641-1 2004 Twenty agonists and nine antagonists were evaluated for their ability to compete for [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT) binding to the cloned human serotonin-1A (ch-5-HT1A) receptor expressed in Chinese hamster ovary cells and for their ability to alter adenylyl cyclase activity in the same cells. 8-Hydroxy-2-(di-n-propylamino)tetralin 90-128 5-hydroxytryptamine receptor 1A Homo sapiens 191-207 15482641-1 2004 Twenty agonists and nine antagonists were evaluated for their ability to compete for [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT) binding to the cloned human serotonin-1A (ch-5-HT1A) receptor expressed in Chinese hamster ovary cells and for their ability to alter adenylyl cyclase activity in the same cells. 8-Hydroxy-2-(di-n-propylamino)tetralin 135-144 5-hydroxytryptamine receptor 1A Homo sapiens 191-207 15190115-2 2004 We have demonstrated previously, using immunoelectron microscopy with specific 5-HT1A antibodies, that an internalization of 5-HT1A autoreceptors is associated with their desensitization in rats given a single dose of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin. 8-Hydroxy-2-(di-n-propylamino)tetralin 246-284 5-hydroxytryptamine receptor 1A Homo sapiens 125-131 15152026-1 2004 The serotonin (5-hydroxytryptamine1A) 5-HT1A receptor agonist 8-OH-DPAT [(R)- (+)-8-hydroxy-2-(di-n-propylamino)tetralin] inhibits bladder activity under nociceptive but not innocuous conditions in cats with an intact spinal cord, suggestive of an effect on primary afferent C fibers or their targets. 8-Hydroxy-2-(di-n-propylamino)tetralin 62-71 5-hydroxytryptamine receptor 1A Homo sapiens 38-44 14656287-9 2003 8-OH-DPAT, a 5-HT1A receptor agonist, also inhibited Ca(2+) currents in dissociated neurons. 8-Hydroxy-2-(di-n-propylamino)tetralin 0-9 5-hydroxytryptamine receptor 1A Homo sapiens 13-28 15628665-4 2004 We report here the pharmacological characterization of one of the first isolated clones of CHO cells stably expressing the human 5-HT1A receptor using the selective agonist 8-OH-DPAT and antagonist p-MPPF. 8-Hydroxy-2-(di-n-propylamino)tetralin 173-182 5-hydroxytryptamine receptor 1A Homo sapiens 129-144 14556235-5 2003 In CHO-K1 cells expressing 5-HT1A receptors, 5-HT and DA inhibited the specific binding of selective antagonist [3H]-8-OH-DPAT with IC50 values of 10.2 nM and 1.4 microM, and both 5-HT and DA inhibited the forskolin-induced accumulation of cAMP. 8-Hydroxy-2-(di-n-propylamino)tetralin 117-126 5-hydroxytryptamine receptor 1A Homo sapiens 27-33 14614949-0 2003 Contribution of the serotonin 5-HT1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats. 8-Hydroxy-2-(di-n-propylamino)tetralin 57-66 5-hydroxytryptamine receptor 1A Homo sapiens 30-36 12885442-6 2003 Microinjections of the 5-HT(1A) receptor agonist 8-OHDPAT (0.1, 1.0 and 3.0 nmol) into the medial hypothalamus suppressed PAG-elicited hissing in a dose-dependent manner. 8-Hydroxy-2-(di-n-propylamino)tetralin 49-57 5-hydroxytryptamine receptor 1A Homo sapiens 23-40 12923612-5 2003 The selective antagonists p-MPPI and WAY100,635 abolished stimulation of binding by (+)8-OH-DPAT, clozapine and S16924 (p-MPPI), indicating that these actions were mediated specifically by 5-HT(1A) receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 84-96 5-hydroxytryptamine receptor 1A Homo sapiens 189-196 12885442-7 2003 Administration of the 5-HT(1A) antagonist p-MPPI (3.0 nmol) blocked the suppressive effects of 8-OHDPAT upon hissing. 8-Hydroxy-2-(di-n-propylamino)tetralin 95-103 5-hydroxytryptamine receptor 1A Homo sapiens 22-29 12892833-7 2003 The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) impaired this response, suggesting an anxiolytic effect, and the preferential 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) was ineffective. 8-Hydroxy-2-(di-n-propylamino)tetralin 28-67 5-hydroxytryptamine receptor 1A Homo sapiens 4-19 12892833-7 2003 The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) impaired this response, suggesting an anxiolytic effect, and the preferential 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) was ineffective. 8-Hydroxy-2-(di-n-propylamino)tetralin 69-78 5-hydroxytryptamine receptor 1A Homo sapiens 4-19 12818723-4 2003 Thus, after stimulation with forskolin, the agonists dopamine (at D(2A) and D(3)), noradrenaline (at alpha(2C)), or 8-OH-DPAT (at 5-HT(1A)) induced a reduction in cAMP accumulation. 8-Hydroxy-2-(di-n-propylamino)tetralin 116-125 5-hydroxytryptamine receptor 1A Homo sapiens 130-137 12763095-3 2003 Using conventional whole-cell patch recording, we confirmed that the 5-HT(1A) agonist, 8-hydroxy-2-dipropylaminotetralin, presynaptically decreased electrically evoked GABA release while the 5-HT(3) agonist, m-chlorophenylbiguanide (mCPBG), presynaptically facilitated release. 8-Hydroxy-2-(di-n-propylamino)tetralin 87-120 5-hydroxytryptamine receptor 1A Homo sapiens 69-76 12004193-3 2002 In addition, the finding that 8-OH-DPAT, CGS-12066A and SC53116 also inhibited AVP-induced flank marking suggests that 5-HT could also inhibit flank marking by acting through 5-HT1A, 5-HT7, 5-HT1B and/or 5-HT4 receptor subtypes. 8-Hydroxy-2-(di-n-propylamino)tetralin 30-39 5-hydroxytryptamine receptor 1A Homo sapiens 175-181 12787852-2 2003 In view of a role of 5-hydroxytryptamine (5-HT; serotonin)-1A receptors in the elicitation of EPS, the present study concerns pre- and postsynaptic responses to a selective 5-HT-1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) following acute and chronic administration of haloperidol in rats. 8-Hydroxy-2-(di-n-propylamino)tetralin 199-238 5-hydroxytryptamine receptor 1A Homo sapiens 173-189 12626670-2 2003 In current-clamp mode, activation of 5-HT1A receptors by 8-OH-DPAT led to depolarization and an increase in input resistance in most motoneurons but caused hyperpolarization and a decrease in input resistance in the remaining smaller fraction of cells. 8-Hydroxy-2-(di-n-propylamino)tetralin 57-66 5-hydroxytryptamine receptor 1A Homo sapiens 37-43 12676358-1 2003 The 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2-5 cells. 8-Hydroxy-2-(di-n-propylamino)tetralin 21-60 5-hydroxytryptamine receptor 1A Homo sapiens 4-11 12676358-1 2003 The 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2-5 cells. 8-Hydroxy-2-(di-n-propylamino)tetralin 62-71 5-hydroxytryptamine receptor 1A Homo sapiens 4-11 12676358-2 2003 Two 5-HT(1A) agonists, Repinotan hydrochloride (BAY x 3702) and 8-OH-DPAT, block caspase-3 activation and apoptosis caused by anoxia/reoxygenation and H(2)O(2) treatment. 8-Hydroxy-2-(di-n-propylamino)tetralin 64-73 5-hydroxytryptamine receptor 1A Homo sapiens 4-11 12676358-7 2003 Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3). 8-Hydroxy-2-(di-n-propylamino)tetralin 73-82 5-hydroxytryptamine receptor 1A Homo sapiens 204-211 12684269-4 2003 Ligand binding studies were used to determine dissociation constants for agonist binding to the 5-HT(1A) receptor: (a) K(i) values for agonists were determined in competition versus the binding of the agonist [(3)H]-8-OH DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 216-225 5-hydroxytryptamine receptor 1A Homo sapiens 96-113 12588512-4 2003 The 5-HT(1A) agonist 8-OH-DPAT, which had no effect on vasopressin secretion, stimulated oxytocin secretion. 8-Hydroxy-2-(di-n-propylamino)tetralin 21-30 5-hydroxytryptamine receptor 1A Homo sapiens 4-11 12237254-6 2002 5 The proportion of 5-HT(1A) receptor binding sites detected by [(3)H]-MPPF that displayed high affinity for 8-OH-DPAT was significantly greater when the interacting G protein contained isoleucine rather than glycine at residue(351). 8-Hydroxy-2-(di-n-propylamino)tetralin 109-118 5-hydroxytryptamine receptor 1A Homo sapiens 20-37 12237254-8 2002 7 These results indicate that a higher avidity ternary complex is formed between 8-OH-DPAT, the 5-HT(1A) receptor and G proteins when isoleucine rather than glycine is located at residue(351) of the interacting G protein. 8-Hydroxy-2-(di-n-propylamino)tetralin 81-90 5-hydroxytryptamine receptor 1A Homo sapiens 96-113 12649391-7 2003 All thermic responses to 8-OH-DPAT, including the lethality, were effectively blocked by pretreatment with the 5-HT(1A) receptor antagonist WAY100635, suggesting line differences in thermoregulatory circuits that are influenced by 5-HT(1A) receptor activation. 8-Hydroxy-2-(di-n-propylamino)tetralin 25-34 5-hydroxytryptamine receptor 1A Homo sapiens 111-128 12649391-7 2003 All thermic responses to 8-OH-DPAT, including the lethality, were effectively blocked by pretreatment with the 5-HT(1A) receptor antagonist WAY100635, suggesting line differences in thermoregulatory circuits that are influenced by 5-HT(1A) receptor activation. 8-Hydroxy-2-(di-n-propylamino)tetralin 25-34 5-hydroxytryptamine receptor 1A Homo sapiens 231-248 12166089-4 2002 The 5-HT and other 5-HT1A receptor agonists, flesinoxan and 8-hydroxy-2- (di-n-propylamino)tetralon (8-OH-DPAT), significantly decreased the population excitatory postsynaptic potential (EPSP) in the CA3-CA1 excitatory synapse in a dose-dependent manner. 8-Hydroxy-2-(di-n-propylamino)tetralin 101-110 5-hydroxytryptamine receptor 1A Homo sapiens 19-34 11746722-6 2001 When the 5-HT(1A) receptor agonist 8-OH-DPAT was administered intravenously at a dose of 0.1, 0.3, or 1 mg/kg 30 min after tracer injection, binding of [carbonyl-(11)C]WAY-100635 was displaced in both age groups in a dose-dependent manner. 8-Hydroxy-2-(di-n-propylamino)tetralin 35-44 5-hydroxytryptamine receptor 1A Homo sapiens 9-26 12031873-6 2002 However, addition of the specific 5-HT(1A) receptor agonist 8-OH-DPAT as well as the alpha1-adrenoceptor antagonist prazosin could not substantially block this tracer accumulation. 8-Hydroxy-2-(di-n-propylamino)tetralin 60-69 5-hydroxytryptamine receptor 1A Homo sapiens 34-51 11889759-3 2002 Based on our previous experimental studies that 8-OH-DPAT, a potent 5-HT1A agonist, attenuates an increase in L-DOPA-induced extracellular DA in the striatum of the rat model of Parkinson"s disease, we hypothesized that L-DOPA-induced dyskinesia in patients with Parkinson"s disease is alleviated by a 5-HT1A agonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 48-57 5-hydroxytryptamine receptor 1A Homo sapiens 302-308 11897085-4 2002 5-HT1A binding sites, as labeled with [3H]8-hydroxy-dipropylaminotetralin (8-OH-DPAT), were highest in the superficial, retinorecipient layers of the tectum, intermediate in layers 6 and 7 and low in the remaining layers. 8-Hydroxy-2-(di-n-propylamino)tetralin 75-84 5-hydroxytryptamine receptor 1A Homo sapiens 0-6 11746722-9 2001 In addition, these observations suggested that the age-related impairment of 5-HT(1A) receptor responses to 8-OH-DPAT might be related to the reduced efficacy of antidepressant therapy in elderly patients with depression. 8-Hydroxy-2-(di-n-propylamino)tetralin 108-117 5-hydroxytryptamine receptor 1A Homo sapiens 77-94 11606626-2 2001 In nucleus raphe dorsalis (NRD) and hippocampus (CA3), the selective 5-HT(1A) agonist (+)-8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) reduces the firing activity of serotoninergic (5-HT) and pyramidal neurons, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 86-129 5-hydroxytryptamine receptor 1A Homo sapiens 69-76 11606626-2 2001 In nucleus raphe dorsalis (NRD) and hippocampus (CA3), the selective 5-HT(1A) agonist (+)-8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) reduces the firing activity of serotoninergic (5-HT) and pyramidal neurons, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 131-140 5-hydroxytryptamine receptor 1A Homo sapiens 69-76 11275281-0 2001 Role of 5-HT(1A) and 5-HT(7) receptors in the facilitatory response induced by 8-OH-DPAT on learning consolidation. 8-Hydroxy-2-(di-n-propylamino)tetralin 79-88 5-hydroxytryptamine receptor 1A Homo sapiens 8-15 11595206-0 2001 Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils. 8-Hydroxy-2-(di-n-propylamino)tetralin 96-105 5-hydroxytryptamine receptor 1A Homo sapiens 81-87 11595206-3 2001 Diazepam (0.1 mg/kg) and the 5-HT(1A) receptor agonist 8-OH-DPAT (0.003 and 0.01 mg/kg) also increased social interaction, whereas an acute dose of the selective serotonin re-uptake inhibitor fluoxetine (10 mg/kg) decreased the time spent in social interaction. 8-Hydroxy-2-(di-n-propylamino)tetralin 55-64 5-hydroxytryptamine receptor 1A Homo sapiens 29-46 11569620-0 2001 Effects of histidine on working memory deficits induced by the 5-HT1A-receptor agonist 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 87-96 5-hydroxytryptamine receptor 1A Homo sapiens 63-78 11569620-1 2001 We investigated the effects of histidine on spatial memory deficits induced by the 5-HT1A-receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). 8-Hydroxy-2-(di-n-propylamino)tetralin 108-146 5-hydroxytryptamine receptor 1A Homo sapiens 83-98 11448518-7 2001 8-Hydroxy-di-n-propylamino tetralin (8-OH-DPAT), a selective 5-HT(1A) agonist, mimicked the facilitation of 5-HT. 8-Hydroxy-2-(di-n-propylamino)tetralin 37-46 5-hydroxytryptamine receptor 1A Homo sapiens 61-68 11275281-9 2001 The present results suggest that the enhancing effect produced by 8-OH-DPAT on learning consolidation involves activation of 5-HT(1A) receptors and an additional mechanism, probably related to the 5-HT(7) receptor. 8-Hydroxy-2-(di-n-propylamino)tetralin 66-75 5-hydroxytryptamine receptor 1A Homo sapiens 125-132 11164517-6 2001 The administration of the selective 5-HT1A agonist, 8-OH-DPAT, counteracted the CTAs produced by MB and 7-NI. 8-Hydroxy-2-(di-n-propylamino)tetralin 52-61 5-hydroxytryptamine receptor 1A Homo sapiens 36-42 11330332-4 2001 Both 8-OH-DPAT (1 microM) and 5-HT (10 microM) elicited a pronounced increase in [35S]GTPyS binding in the dorsal raphe nucleus, which contains serotonergic cell bodies bearing 5-HT1A autoreceptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 5-14 5-hydroxytryptamine receptor 1A Homo sapiens 177-183 11330332-6 2001 In the dentate gyrus, lateral septum and entorhinal cortex, structures enriched in postsynaptic 5-HT1A receptors, 8-OH-DPAT (1 microM) and 5-HT (10 microM) also elicited a marked increase in [35S]GTPgammaS binding which was likewise blocked by pindolol. 8-Hydroxy-2-(di-n-propylamino)tetralin 114-123 5-hydroxytryptamine receptor 1A Homo sapiens 96-102 11287817-6 2001 ), a 5-HT reuptake inhibitor, and 8-hydroxy-2-(di-n-propylamino)tetralin, a 5-HT(1A) receptor agonist, also suppressed the HTR induced by BZ-RAs. 8-Hydroxy-2-(di-n-propylamino)tetralin 34-72 5-hydroxytryptamine receptor 1A Homo sapiens 76-93 11135008-2 2001 We found that 8-hydroxy-2-(n-dipropylamino)tetralin hydrobromide (8-OH-DPAT), a selective 5-HT1A receptor agonist, induced a dose-dependent increase in wakefulness (W) and decrease in deep slow-wave sleep (SWS), but had no significant effect on the generation of paradoxical sleep (PS) at concentrations of 5-500 microM. 8-Hydroxy-2-(di-n-propylamino)tetralin 66-75 5-hydroxytryptamine receptor 1A Homo sapiens 90-105 11077069-8 2001 Both the degree of 5-HT(1A) receptor activation by 8-OH-DPAT and (-)-pindolol, and its inhibition by spiperone, strongly correlate (r(2): 0.78-0.81) with the octanol/water partition coefficients of the mutated amino acid at position 351 of the G(alphai3) protein. 8-Hydroxy-2-(di-n-propylamino)tetralin 51-60 5-hydroxytryptamine receptor 1A Homo sapiens 19-36 10991934-2 2000 We studied the effects of low doses of 8-OH-DPAT, a 5-HT(1A) receptor agonist, on the impairment of spatial learning caused by scopolamine injected into the CA1 region of the dorsal hippocampus of rats performing a two-platform spatial discrimination task. 8-Hydroxy-2-(di-n-propylamino)tetralin 39-48 5-hydroxytryptamine receptor 1A Homo sapiens 52-69 11069935-7 2000 Both nifedipine, an L-type Ca(2+) channel antagonist, and omega-conotoxin GVIA, a selective N-type channel blocker, abolished the induction of associative LTD. 8-hydroxy-2-dipropylaminotetralin (OH-DPAT), a 5-HT(1A) receptor agonist, inhibited postsynaptic Ca(2+) influx through N-type Ca(2+) channels, without affecting presynaptic transmitter release. 8-Hydroxy-2-(di-n-propylamino)tetralin 160-193 5-hydroxytryptamine receptor 1A Homo sapiens 207-224 11198126-6 2000 Administration of the 5-HT1A antagonists WAY-100635 and NAN-190 alone produced dose-dependent rate-decreasing effects, but the effects on accuracy of responding in the acquisition components differed from those of the 5-HT1A agonists (8-OH-DPAT and LY228729), in that they did not produce an increase in the percentage of errors. 8-Hydroxy-2-(di-n-propylamino)tetralin 235-244 5-hydroxytryptamine receptor 1A Homo sapiens 22-28 10952674-6 2000 Finally, the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 1 microM) inhibited the NMDA-evoked cyclic GMP response, an effect blocked by the selective 5-HT(1A) receptor antagonist WAY 100635. 8-Hydroxy-2-(di-n-propylamino)tetralin 30-69 5-hydroxytryptamine receptor 1A Homo sapiens 174-191 10936212-2 2000 Serotonin, (R)-8-hydroxy-2-dipropylaminotetralin [(R)-8-OH-DPAT], and buspirone inhibited cyclic AMP production in cells expressing native and mutant 5-HT(1A) receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 11-48 5-hydroxytryptamine receptor 1A Homo sapiens 150-157 10936212-2 2000 Serotonin, (R)-8-hydroxy-2-dipropylaminotetralin [(R)-8-OH-DPAT], and buspirone inhibited cyclic AMP production in cells expressing native and mutant 5-HT(1A) receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 50-63 5-hydroxytryptamine receptor 1A Homo sapiens 150-157 10952674-6 2000 Finally, the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 1 microM) inhibited the NMDA-evoked cyclic GMP response, an effect blocked by the selective 5-HT(1A) receptor antagonist WAY 100635. 8-Hydroxy-2-(di-n-propylamino)tetralin 71-80 5-hydroxytryptamine receptor 1A Homo sapiens 174-191 10541727-7 1999 The prototypical 5-HT(1A) agonist, 8-OH-DPAT [8-hydroxy-(2-di-n-propylamino)tetralin] substituted for LY233708. 8-Hydroxy-2-(di-n-propylamino)tetralin 35-44 5-hydroxytryptamine receptor 1A Homo sapiens 17-24 10900249-5 2000 and s.c. administration, LY426965 blocked the lower lip retraction, flat body posture, hypothermia, and increase in rat serum corticosterone induced by the 5-HT(1A) agonist 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin). 8-Hydroxy-2-(di-n-propylamino)tetralin 173-182 5-hydroxytryptamine receptor 1A Homo sapiens 156-163 10900249-5 2000 and s.c. administration, LY426965 blocked the lower lip retraction, flat body posture, hypothermia, and increase in rat serum corticosterone induced by the 5-HT(1A) agonist 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin). 8-Hydroxy-2-(di-n-propylamino)tetralin 184-217 5-hydroxytryptamine receptor 1A Homo sapiens 156-163 10676857-1 2000 The stereoselectivity of the serotonin1A (5-HT1A) receptor compound 8-hydroxy-2(di-N-propylamino)tetralin (8-OH-DPAT) on forskolin-stimulated adenylyl cyclase activity was investigated in membranes from human 5-HT pre-synaptic (raphe nuclei) and post-synaptic (hippocampus and prefrontal cortex) regions of autopsy brains. 8-Hydroxy-2-(di-n-propylamino)tetralin 68-105 5-hydroxytryptamine receptor 1A Homo sapiens 29-58 10676857-1 2000 The stereoselectivity of the serotonin1A (5-HT1A) receptor compound 8-hydroxy-2(di-N-propylamino)tetralin (8-OH-DPAT) on forskolin-stimulated adenylyl cyclase activity was investigated in membranes from human 5-HT pre-synaptic (raphe nuclei) and post-synaptic (hippocampus and prefrontal cortex) regions of autopsy brains. 8-Hydroxy-2-(di-n-propylamino)tetralin 107-116 5-hydroxytryptamine receptor 1A Homo sapiens 29-58 10515324-4 1999 Tests for generalization and antagonism showed that 5-HT1A receptor agonists, such as 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (66.7%), flesinoxan (72.7%), buspirone (58.3%), and ipsapirone (36.4%) only partially substituted for the eltoprazine cue. 8-Hydroxy-2-(di-n-propylamino)tetralin 86-95 5-hydroxytryptamine receptor 1A Homo sapiens 52-67 10884564-3 2000 Microiontophoretic ejection of either the selective serotonin(1A) (5-HT(1A)) agonist (+)8-OH-DPAT or the 5-HT(1B/1D) agonist alniditan resulted in the reversible suppression of the response to superior sagittal sinus stimulation of 29/46 and 18/20 trigeminal neurones, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 88-97 5-hydroxytryptamine receptor 1A Homo sapiens 67-74 10884564-5 2000 Microiontophoretic ejection of the selective 5-HT(1A) receptor antagonist WAY-100635 significantly antagonised the effect of (+)8-OH-DPAT (effect reduced by 30%, P<0.05). 8-Hydroxy-2-(di-n-propylamino)tetralin 128-137 5-hydroxytryptamine receptor 1A Homo sapiens 45-62 10882396-5 2000 Saturation studies using [(3)H]-8-OH-DPAT and [(3)H]-MPPF revealed a single, high affinity site (K(D)approximately 1 nM) in HEK293 cells expressing human 5-HT(1A) receptors and rat cortex. 8-Hydroxy-2-(di-n-propylamino)tetralin 32-41 5-hydroxytryptamine receptor 1A Homo sapiens 154-161 10899359-0 2000 MDMA stimulus generalization to the 5-HT(1A) serotonin agonist 8-hydroxy-2- (di-n-propylamino)tetralin. 8-Hydroxy-2-(di-n-propylamino)tetralin 63-102 5-hydroxytryptamine receptor 1A Homo sapiens 36-43 10823340-6 2000 Systemic administration of the selective 5-HT1A receptor agonist 8-OHDPAT induces dose-dependent effects; i.e. low doses increase slow wave sleep and reduce waking, whereas large doses increase waking and reduce slow wave sleep and REM sleep. 8-Hydroxy-2-(di-n-propylamino)tetralin 65-73 5-hydroxytryptamine receptor 1A Homo sapiens 41-56 10541727-7 1999 The prototypical 5-HT(1A) agonist, 8-OH-DPAT [8-hydroxy-(2-di-n-propylamino)tetralin] substituted for LY233708. 8-Hydroxy-2-(di-n-propylamino)tetralin 46-84 5-hydroxytryptamine receptor 1A Homo sapiens 17-24 10100214-9 1999 [11C]NAD-299 binding was inhibited by addition of the 5-HT1A receptor ligands WAY-100635, pindolol, (+/-)-8-OH-DPAT, 5-HT, and buspirone, leaving a low background of nonspecific binding. 8-Hydroxy-2-(di-n-propylamino)tetralin 100-115 5-hydroxytryptamine receptor 1A Homo sapiens 54-69 10412836-0 1999 Modulation of sympathetic nerve activity by microinjection of the 5-HT1A receptor agonist 8-OH-DPAT into the rostroventrolateral medulla. 8-Hydroxy-2-(di-n-propylamino)tetralin 90-99 5-hydroxytryptamine receptor 1A Homo sapiens 66-81 10412836-6 1999 This study demonstrates that differential inhibition of regional sympathetic outflows can be elicited by microinjection of the 5-HT1A receptor agonist 8-OH-DPAT into the RVLM. 8-Hydroxy-2-(di-n-propylamino)tetralin 151-160 5-hydroxytryptamine receptor 1A Homo sapiens 127-142 10379620-4 1999 RESULTS: Firstly, the 5-HT1A agonists 8-OH-DPAT and ipsapirone attenuated the extrapyramidal-like effects of haloperidol and risperidone more than their therapeutic-like effects; this was not observed for tropapride, where all of its effects were markedly attenuated. 8-Hydroxy-2-(di-n-propylamino)tetralin 38-47 5-hydroxytryptamine receptor 1A Homo sapiens 22-28 10379620-6 1999 Thirdly, neuroleptics apparently differed in their sensitivity to interactions with 5-HT1A agonists inasmuch as 8-OH-DPAT and ipsapirone attenuated the effects of tropapride on hindlimb retraction times more than those of haloperidol or risperidone. 8-Hydroxy-2-(di-n-propylamino)tetralin 112-121 5-hydroxytryptamine receptor 1A Homo sapiens 84-90 10188639-5 1999 Similarly, quantitative autoradiography using the radiolabeled 5-HT(1A) receptor agonist 8-hydroxy-2-(di-N-propylamino) tetralin demonstrated a significant decline in receptor density in 3- and 13-month MC and HC groups as compared to age-matched LC groups in the hippocampus. 8-Hydroxy-2-(di-n-propylamino)tetralin 89-128 5-hydroxytryptamine receptor 1A Homo sapiens 63-80 9744926-7 1998 Although the serotonin agonists for the 5-HT1B,2C,3 receptors were ineffective, the effects were mimicked by the 5-HT1A-receptor agonists (8-OH-DPAT, 5-CT) and prevented by the 5-HT1A-receptor antagonist NAN-190. 8-Hydroxy-2-(di-n-propylamino)tetralin 139-148 5-hydroxytryptamine receptor 1A Homo sapiens 113-128 9836617-1 1998 A series of four racemic ring-substituted trans-2-(indol-3-yl)cyclopropylamine derivatives was synthesized and tested for affinity at the 5-HT1A receptor, by competition with [3H]-8-OH-DPAT in rat hippocampal homogenates, and for affinity at the agonist-labeled cloned human 5-HT2A, 5-HT2B, and 5-HT2C receptor subtypes. 8-Hydroxy-2-(di-n-propylamino)tetralin 180-189 5-hydroxytryptamine receptor 1A Homo sapiens 138-153 9817696-2 1998 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a 5-HT1A and 5-HT7 agonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 0-38 5-hydroxytryptamine receptor 1A Homo sapiens 56-62 9817696-2 1998 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a 5-HT1A and 5-HT7 agonist. 8-Hydroxy-2-(di-n-propylamino)tetralin 40-49 5-hydroxytryptamine receptor 1A Homo sapiens 56-62 9826061-0 1998 Dimerization of 8-OH-DPAT increases activity at serotonin 5-HT1A receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 16-25 5-hydroxytryptamine receptor 1A Homo sapiens 58-64 9826061-6 1998 Hence, the 8-OH-DPAT dimer shows increased efficacy at 5-HT1A receptors compared to 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 11-20 5-hydroxytryptamine receptor 1A Homo sapiens 55-61 9878719-4 1999 5-HT and the 5-HT1A receptor agonist, (+)8-hydroxy-2(di-N-propylamino)tetraline (8-OH-DPAT), were able to inhibit forskolin-stimulated adenylyl cyclase activity in a dose-dependent manner for 48 h after death in rat and human brain. 8-Hydroxy-2-(di-n-propylamino)tetralin 81-90 5-hydroxytryptamine receptor 1A Homo sapiens 13-28 9878719-11 1999 The (+)8-OH-DPAT dose-response curve was completely reversed by 5-HT1A receptor antagonists in rat cortex and all human brain areas. 8-Hydroxy-2-(di-n-propylamino)tetralin 7-16 5-hydroxytryptamine receptor 1A Homo sapiens 64-79 9845002-4 1998 The main response to serotonin application (2-20 microM) was an inhibition that could be mimicked by 8-OH-DPAT (a 5-HT1A receptor agonist). 8-Hydroxy-2-(di-n-propylamino)tetralin 101-110 5-hydroxytryptamine receptor 1A Homo sapiens 114-129 12580024-13 1998 The selective 5-HT1A agonist (+)-8-OH-DPAT (10(-8)-10(-5) M) had no significant effect, but at concentration of 10(-4) M, inhibited evoked 3H-Ach. 8-Hydroxy-2-(di-n-propylamino)tetralin 29-42 5-hydroxytryptamine receptor 1A Homo sapiens 14-20 9721928-3 1998 We constructed cumulative concentration response curves to the selective 5-HT1A agonist (+)-8-OH-DPAT on both extracellular recordings of 5-HT neurones and electrically stimulated 5-HT release in dorsal raphe brain slices. 8-Hydroxy-2-(di-n-propylamino)tetralin 88-101 5-hydroxytryptamine receptor 1A Homo sapiens 73-79 9721928-4 1998 Chronic paroxetine desensitized the 5-HT1A receptors controlling firing, with an increase in EC50 from 10.7 nM to 46.2 nM 8-OH-DPAT. 8-Hydroxy-2-(di-n-propylamino)tetralin 122-131 5-hydroxytryptamine receptor 1A Homo sapiens 36-42 9871775-4 1998 Surprisingly enough, the dimer of 8-OH-DPAT 6 binds to 5HT1A, 5HT1B and 5HT1D receptors with similar high affinity. 8-Hydroxy-2-(di-n-propylamino)tetralin 34-43 5-hydroxytryptamine receptor 1A Homo sapiens 55-60 9920534-5 1998 The selective 5-HT1A receptor antagonist WAY100635 produced a potent (IC50, 2.3 nM) and complete block of the 8-OH-DPAT-stimulated response. 8-Hydroxy-2-(di-n-propylamino)tetralin 110-119 5-hydroxytryptamine receptor 1A Homo sapiens 14-29 9651229-5 1998 Discharge activity of REM-on neurons was almost completely suppressed by local microdialysis perfusion of the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), although this agonist had minimal or no effect on the Wake/REM-on neurons. 8-Hydroxy-2-(di-n-propylamino)tetralin 135-174 5-hydroxytryptamine receptor 1A Homo sapiens 120-126 9651229-5 1998 Discharge activity of REM-on neurons was almost completely suppressed by local microdialysis perfusion of the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), although this agonist had minimal or no effect on the Wake/REM-on neurons. 8-Hydroxy-2-(di-n-propylamino)tetralin 176-185 5-hydroxytryptamine receptor 1A Homo sapiens 120-126 9435153-5 1998 In contrast to sigma ligands and other reference compounds, the 5-HT1A agonists buspirone, 8-OH-DPAT and spiroxatrine dose-dependently produced BMY 14802-like discriminative stimulus effects. 8-Hydroxy-2-(di-n-propylamino)tetralin 91-100 5-hydroxytryptamine receptor 1A Homo sapiens 64-70 9536454-3 1998 The data indicate that the reversal of haloperidol-induced EPS by (+/-)-8-OH-DPAT and its enantiomers is mediated via effects at 5-HT1A receptors, not dopamine D2 receptors. 8-Hydroxy-2-(di-n-propylamino)tetralin 66-81 5-hydroxytryptamine receptor 1A Homo sapiens 129-135 9553162-18 1998 Receptor-specific binding was eliminated in the presence of the selective 5-HT1A receptor agonist, 8-OH-DPAT [(+/-)-8-hydroxy-2-dipropylaminotetralin]. 8-Hydroxy-2-(di-n-propylamino)tetralin 99-108 5-hydroxytryptamine receptor 1A Homo sapiens 74-89 9553162-18 1998 Receptor-specific binding was eliminated in the presence of the selective 5-HT1A receptor agonist, 8-OH-DPAT [(+/-)-8-hydroxy-2-dipropylaminotetralin]. 8-Hydroxy-2-(di-n-propylamino)tetralin 110-149 5-hydroxytryptamine receptor 1A Homo sapiens 74-89 9884126-6 1998 They demonstrated: (1) that the androgenic and estrogenic metabolites of testosterone differentially modulate the ability of systemically administered 8-OH-DPAT (a 5HT1A agonist) and CGS12066B (a 5HT1B agonist) to decrease offensive aggression; and (2) when microinjected into the lateral septum (LS) or medial preoptic area (MPO), the aggression-attenuating effects of 1A and 1B agonists differ regionally and vary with the steroidal milieu. 8-Hydroxy-2-(di-n-propylamino)tetralin 151-160 5-hydroxytryptamine receptor 1A Homo sapiens 164-169